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ABSTRACT 
A set of studies was designed in order to better understand the exposure of horses in 
Canada to Ixodes-borne diseases, namely equine granulocytic anaplasmosis (EGA, caused 
by Anaplasma phagocytophilum) and Lyme borreliosis (LB, caused by Borrelia 
burgdorferi).  
In the first study, equine serum samples submitted to veterinary diagnostic  
laboratories in SK, MB and ON were tested for antibodies against A. phagocytophilum 
and B. burgdorferi, using the point-of-care SNAP® 4Dx® ELISA. Horses seropositive to 
EGA were found in SK and MB and horses seropositive to LB were found in SK, MB and 
ON. Overall seroprevalence according to the SNAP® 4Dx® ELISA was 0.53% for EGA 
and 1.6% for LB.  Samples that tested positive for antibodies against A. phagocytophilum 
(n=2) and B. burgdorferi (n=6) by SNAP® 4Dx® ELISA and 2 randomly selected subsets 
of samples that tested negative (n=92 each) were then re-tested using currently 
recommended serologic methods, and test results were compared. A lack of agreement 
was found between the SNAP® 4Dx® ELISA and indirect immunofluorescent assay 
(IFA) for EGA (McNemar test p = 0.000001). Agreement of the SNAP® 4Dx® ELISA 
and ELISA confirmed with Western Blot (WB) for LB was only fair (Kappa 0.23). Due to 
the lack of agreement between serologic tests for EGA and LB in the first study, another 
study to further evaluate the agreement among available serologic tests was conducted.  
A set of 50 convenience serum samples submitted to the veterinary diagnostic 
laboratory in SK was tested by SNAP® 4Dx® Plus ELISA for antibodies against A. 
phagocytophilum and B. burgdorferi. Samples were also tested by IFA for antibodies 
against A. phagocytophilum in two referral laboratories, and by IFA, ELISA confirmed 
with WB and Equine Lyme multiplex assay for antibodies against B. burgdorferi in three 
referral laboratories. Again, test results varied between the different tests. For EGA, all 3 
pair-wise test comparisons lacked agreement. For LB, agreement between tests ranged 
from poor to fair. Differences in test methodology and antigens used, cut-off settings 
between the laboratories and false positive or false negative results are likely the cause for 
the different assessment of the same sample as seropositive or seronegative. 
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In the third study, the goal was to describe potential risk factors for exposure of horses 
in Canada to EGA and LB. Management factors in horses that tested seropositive or 
seronegative for EGA or LB, respectively, in the previous studies were evaluated. Horse 
owners were surveyed with regard to their horses’ signalment, timing of pasture housing, 
and province of residence, travel history, tick infestation history, history of Lyme 
vaccination and history of previously diagnosed tick-borne disease. Response rate (11.5%) 
and the number of seropositive horses available for evaluation were low, which precluded 
statistical analysis. The majority of seropositive horses resided in SK, was pastured in the 
fall, did not have a recent travel history and had not had visible tick infestation. These 
observations supported exposure of horses to tick-borne diseases within Canada. Potential 
risk factors require further investigation.  
As information about tick infestation in horses is scarce in general, a passive 
surveillance study of horse ticks in SK was conducted in 2012 and 2013. A total of 833 
ticks from over 86 horses were received. All ticks were Dermacentor species, i.e. D. 
albipictus, D. andersoni and D. variabilis. D. albipictus ticks were mostly received in 
February and March, D. andersoni mainly in April and June and D. variabilis mostly in 
May and June. Geographic distribution of the species in SK was similar to that previously 
reported based on active and passive surveillance. No Ixodes species were received.   
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1. REVIEW OF THE LITERATURE 
1.1 Ticks and tick-borne diseases of horses in Canada 
1.1.1. Tick infestation of horses in Canada 
1.1.1.1. Dermacentor species 
D. variabilis and D. andersoni are two of the most common tick species in western 
Canada. D. variabilis, also known as the American dog tick, occurs throughout southeastern 
Saskatchewan (SK), southern Manitoba (MB) and Ontario (ON). A few isolated populations 
are also found in Nova Scotia (NS) (1). D. variabilis is usually found in geographic areas 
where summers are warm and humid (1). D. andersoni, also called the Rocky Mountain wood 
tick, occurs throughout the southern parts of British Columbia (BC) and Alberta (AB) as well 
as southwestern SK (1). These ticks are usually found in geographic areas where summers are 
hot and dry. Habitat areas of D. variabilis and D. andersoni are mostly separated from each 
other (1,2); however, occasionally, both species are found together in areas that differ in soil 
moisture and plant populations, i.e. southern central Saskatchewan. The relative importance 
of environmental factors for the abundance and distribution of these tick species in the 
Canadian prairies needs to be further investigated (1).  
D. albipictus, also called the winter tick or the moose tick, is the only Dermacentor tick 
species occurring on only one host. The tick is found all across Canada and its habitat extends 
further north than that of  D. andersoni and D. variabilis (3). Information regarding 
infestation of horses with Dermacentor species is lacking. 
1.1.1.2. Ixodes species 
Ixodes species will be described in detail in the following review. I. scapularis, the 
blacklegged tick, has become established in southern ON, Quebec (QC), MB and NS. I. 
pacificus, the Western blacklegged tick, has mainly become established in southern BC. 
Ixodes species are known to infest horses in North America.  
1.1.2. Potential tick-borne diseases of horses in Canada 
Equine granulocytic anaplasmosis and Lyme borreliosis are transmitted by Ixodes species 
as will be described in detail in this chapter, and both diseases have been reported in horses in 
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Canada (4–8). The current distribution and anticipated geographic expansion of the vector 
Ixodes species in Canada pose a substantial risk of encountering the diseases.  
Equine piroplasmosis, also called babesiosis, is caused by the blood protozoa Theileria 
equi and Babesia caballi in horses. The tropical horse tick, Dermacentor nitens, is the natural 
vector for Theileria equi and Babesia caballi in the US, but has not been reported in Canada. 
Theileria equi has been experimentally transmitted by D. variabilis, D. albipictus and 
Rhipicephalus microplus (formerly known as Boophilus microplus) which does not occur in 
Canada (9).  Equine piroplasmosis has not been reported in Canada to date. 
1.2 Anaplasma phagocytophilum infection 
1.2.1. Etiology 
The genus Anaplasma belongs to the family Anaplasmataceae in the order Rickettsiales 
(10). A. phagocytophilum is an obligatory intracellular bacterium and variants in North 
America are known to cause clinical disease in humans, dogs and horses but not in cattle (11). 
Equine granulocytic anaplasmosis (EGA) is caused by a strain of A. phagocytophilum,  
(previously classified as Ehrlichia equi) that is closely related to the human pathogenic strain 
(12,13). EGA is a tick-borne disease transmitted mostly by the ticks of the Ixodes ricinus 
complex which occur worldwide (14,15). The complex includes Ixodes scapularis (the 
blacklegged tick or deer tick) in the eastern regions of North America, Ixodes pacificus (the 
western blacklegged tick) in the western regions of North America, Ixodes ricinus in northern 
Europe and North Africa, and Ixodes persulcatus in eastern Europe and temperate regions of 
Asia (15). A. phagocytophilum have serologic cross-reactivity with one another and common 
serologic tests cannot differentiate among different strains. A. phagocytophilum strains differ 
in their host infectivity and show minor diversity in their nucleotide sequence of the 16S 
rRNA and the groESLgenes (10). Differences in the 16S rRNA sequence distinguish between 
different variants, such as between AP-Ha, which infects humans and whose reservoir is the 
white footed mouse, and AP Var-1, which is maintained within deer and does not infect 
humans (16). The groESL genes have a structural role and are evolutionarily highly conserved 
genes among bacteria (10). The pathogenic strains of A. phagocytophilum that cause human 
granulocytic anaplasmosis (HGA) and EGA are mostly identical in their 16S and groESL 
genetic sequences in the midwestern US whereas variation exists in the western US 
(10,12,13,16–18).  
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Bacterial cell wall antigens that are expressed inside the mammalian host are commonly 
encoded by the p44 gene family (also called msp2).  The P44 (Msp2) proteins are major 
surface antigens. The A. phagocytophilum genome contains 113 p44 (msp2) genes which 
encode the P44 (Msp2) proteins (10). The p44 (msp2) genes have a central hypervariable 
region and terminal conserved sequences. The P44 proteins vary due to a unidirectional gene 
conversion mechanism and recombination of copies of the gene, which enable antigenic 
variation and avoidance of the immune system (19).  
1.2.2. Hosts and vector ticks 
In the eastern and midwestern US, natural reservoirs of  A. phagocytophilum variants are 
the vertebrate hosts of the blacklegged tick, I. scapularis, which include the white-footed 
mouse, the white-tailed deer, the grey squirrel and the raccoon (16). Seroprevalence of A. 
phagocytophilum infection in white-footed mice in the eastern US ranges from one to 50% 
(13). Information about the natural reservoir for A. phagocytophilum in the western US is 
limited; however, the western blacklegged tick, I. pacificus, is known to feed on lizards, birds, 
small mammals and, occasionally, deer and carnivores (13). The prevalence of infection with 
A. phagocytophilum in Ixodes species is reported to be 14% and 16% in the midwestern and 
northeastern US respectively (20), but is lower in the western US where prevalence values of 
0.8 - 11% have been reported (13). Only nymphs and adult ticks can transfer A. 
phagocytophilum to mammals (10).  
1.2.3. Epidemiology  
Equine granulocytic anaplasmosis was first recognized in horses in California in 1969 
(21), and  was later recognized in other parts of the US and in Europe. In Canada, four cases 
of EGA have been reported since 1996 (4–7), with three of these diagnosed since 2010. None 
of the affected horses had a history of travel, suggesting that they acquired the infection 
within Canada. One of the affected horses resided in Saskatchewan, which is not considered 
endemic for the vector (i.e. Ixodes species). The potential contribution of adventitious ticks to 
disease occurrence in non-endemic areas is discussed later on in this chapter, in the context of 
Lyme borreliosis.  
Clinical cases of EGA are predominantly reported in the winter months, following the 
peak activity of the adult stage of the vector ticks in the fall months. This is similar to the 
disease in dogs but in contrast to human cases, which are reported mainly in the spring and 
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summer months and correlate with the activity of the nymphal stages of the vector. It is 
speculated that transmission of the disease by adult ticks to horses and dogs is more efficient 
(13). It is also possible that humans are more efficient in removing the adult stages of the tick. 
1.2.4. Pathogenesis  
Members of the Anaplasmataceae family replicate in membrane-bound parasitophorous 
vacuoles within the cytoplasm of eukaryotic host cells (10). These bacteria are capable of 
escaping lysosomes by interfering with vesicular movement. As bacteria divide and 
proliferate, the inclusion vacuoles expand to occupy most of the cytoplasm of the infected cell 
(10). Subversion of the innate antimicrobial response increases susceptibility of infected 
individuals to opportunistic infection. A. phagocytophilum inhibits spontaneous and induced 
apoptosis in peripheral neutrophils for up to 96 hours, which enables it to replicate within 24 
hours post infection (10). A phagocytophilum also induces cell autophagy, thus remodeling 
the host cell cytoplasmic space and altering nutrient utilization to accommodate its growth 
(10) 
The site of initial replication of the bacteria after inoculation of the dermis during a tick 
bite is still unknown. In experimentally infected animals, bacteremia was not detected until 72 
to 96 hours after intravenous inoculation with infected blood (16). These findings suggest that 
A. phagocytophilum replicates at the tissue level before bacteremia occurs (16). The 
intracellular bacteria have a tropism toward granulocytes, primarily neutrophils. Endothelial 
cells are also infected and contribute to inflammation by controlling vascular permeability, 
movement of leukocytes and production of inflammatory mediators (22).  
The pathogenesis of granulocytic anaplasmosis in horses involves the presence of a small 
number of the organisms in the blood and it is suggested that disease progression is mediated 
by pro-inflammatory cytokines. In horses that were infected with A. phagocytophilum 
experimentally, up-regulation of expression levels of interleukin (IL)-1β, tumor necrosis 
factor alpha (TNFα) and IL-8 in peripheral leukocytes was observed (23). Pathologically, the 
characteristic gross lesions are hemorrhages, petechiae, ecchymoses and edema, which 
involve the muscles, nerves, brain, heart and kidneys. Histologically, inflammation of the 
small arteries and veins (9) as well as necrotizing vasculitis with perivascular infiltration of 
mononuclear cells and, occasionally, neutrophils has been described (21). 
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1.2.5. Clinical disease in horses 
In horses, the period of bacteremia accompanied by high fever lasts for approximately 
seven days (12,18). Infected horses are often leukopenic, likely due to sequestration of 
infected granulocytes, and are also thrombocytopenic. Depression, anorexia and distal limb 
edema are typical clinical signs and ataxia may occur as well (10). Young horses, i.e. those 
less than 3 years old, tend to have a milder form of the disease (13,24).  
Equine granulocytic anaplasmosis is usually self-limiting as long as no concurrent 
infection with other disease-causing organisms is present. However, a favorable response is 
seen when horses are treated with oxytetracycline and treatment reduces the duration and 
severity of the disease  (24,25). Currently, there is no commercially available vaccine for 
EGA. The main factor in preventing EGA is avoiding exposure to the vector (i.e. Ixodes 
species). Reducing exposure in horses may specifically refer to the fall months when the adult 
stages of Ixodes are active. Because horses are more likely to be infested with the adult tick 
stages (13), it may be necessary to minimize or avoid pasture housing in the fall. 
1.2.6. Currently recommended diagnostic tests 
A. phagocytophilum is an intracellular bacterium and cannot be detected with Gram 
staining (10). Romanowsky staining is usually used. The bacteria then stain purple and the 
characteristic morulae resembling mulberry-like bacterial clumps can be visualized (10). A 
blood smear may reveal morulae inside the cytoplasm of infected circulating granulocytes in 
the first week following infection (10). Sensitivity of detection of the organism in a blood 
smear is relatively low. In human patients with HGA, for example, sensitivity of visual 
detection of morulae is 60% (26) and diagnosis should be supported with molecular or 
serologic methods (27). There are no published data regarding the sensitivity of visual 
detection of A. phagocytophilum morulae in horses affected by EGA. 
Amplification of A. phagocytophilum DNA from whole blood specimens of human 
patients has an estimated sensitivity of 71.4% (26). Due to a lack of standardization, however, 
sensitivity and specificity may vary among different PCR assays (27). The use of tetracycline 
antibiotics prior to testing may further reduce sensitivity (27). There is no published 
information about the sensitivity of PCR in the diagnosis of EGA in horses. 
The indirect immunofluorescence antibody assay (IFA) is a commonly used serologic 
method for detection of antibodies against A. phagocytophilum (27) and is considered the gold 
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standard of serologic testing for rickettsial diseases (27). Serum antibodies bind to a fixed 
antigen on a slide and are detected by identification of a fluorescein-labeled anti-antibody. 
Although IFA remains the principal diagnostic tool for the diagnosis of A. phagocytophilum 
infections, there are no standardized antigens or conjugates, and there is no agreement on 
what constitutes a positive result among the various laboratories providing these tests (21). In 
human patients, IFA is estimated to be 94% to 100% sensitive, depending on the timing of 
sample collection (21). In horses, test sensitivity depends on the horse’s stage of infection at 
the time of sample collection and increases with increased duration of infection (27). Testing 
paired samples collected 21 days apart further increases diagnostic sensitivity (27). Sensitivity 
and specificity of the IFA in horses have not been reported in the literature. 
A commercially available point-of-care SNAP® 4Dx® ELISA (IDEXX Laboratories, 
Westbrook, ME) for simultaneous detection of Dirofilaria immitis antigen and antibodies to 
Borrelia burgdorferi, A. phagocytophilum and Ehrlichia canis was marketed for use in dogs. 
A peptide derived from the immunodominant P44 protein of A. phagocytophilum was used for 
detection of antibodies against this organism. The test was not labeled for use in horses; 
however, anti-antibodies that were used in the test were not species-specific (28,29). 
Chandrashekar et al. (28) reported 100% agreement of the SNAP® 4Dx® ELISA with IFA 
for detection of antibodies against A. phagocytophilum. Samples for this study were obtained 
from presumed infected horses, i.e. horses that had previously been tested for Lyme 
borreliosis, and presumed non-infected horses, i.e. horses that resided in a non-endemic area 
in the US. Lack of gold standard to confirm positive cases and possible cross reactivity were 
not addressed in this study and may be a limitation of this study.  
Recently, a new version of the test that also includes testing for A. platys and E. ewingii 
infection and is called SNAP® 4Dx® Plus ELISA has replaced the SNAP® 4Dx® ELISA. 
According to the manufacturer, comparative trials showed 93.6% agreement between the 
SNAP® 4Dx® ELISA and the newly developed SNAP® 4Dx® Plus ELISA when canine 
samples were tested for antibodies against A. phagoytophilum. 
1.2.6.1. Serologic cross-reactivity 
Antibodies against some species of Ehrlichia may cross-react with Anaplasma antigens 
(27). Using a competitive ELISA based on recombinant A. marginale antigen (Msp5) and an 
IFA based on A. phagocytophilum-infected HL-60 cells, Dreher et al. (30) reported cross-
reactivity in cattle experimentally infected with A. marginale, and in sheep and horses 
7 
 
experimentally infected with A. phagocytophilum. Their findings suggest that antibodies 
against A. marginale may produce a false positive result when testing for antibodies against A. 
phagocytophilum and vice versa.  Cross-reactivity in horses infected with A. marginale in a 
test for antibodies against A. phagocytophilum was not investigated in their study and needs to 
be evaluated as well. A. marginale infection in horses has not been reported and the potential 
significance of cross-reaction is not clear.  
According to the manufacturer, the P44 peptide utilized in the SNAP® 4Dx® and 
SNAP® 4Dx® Plus ELISA does not have any homology to A. marginale Msp2; however, 
cross-reactivity with antibodies against A. platys is possible (Ramaswamy Chandrashekar 
personal communication). A. platys infection in horses has not been reported and the potential 
significance of this cross-reaction is not clear. 
1.2.7. Relationship between seroprevalence and clinical disease 
The presence of antibodies against A. phagocytophilum in horses does not necessarily 
indicate a symptomatic infection, but rather may simply indicate previous exposure to the 
organism. Seroprevalence of EGA, i.e. the overall occurrence of antibodies against A. 
phagocytophilum in horses, may vary between different geographic areas according to the 
infection rate of the vector ticks.  
Although clinical cases of EGA have been reported regularly from the northern coast 
counties of California, Madigan et al. documented a seroprevalence of only 10% in horses 
residing in the California Coast Range and the Sierra foothills (31). In clinically normal 
horses from areas in Minnesota and Wisconsin, where established populations of I. scapularis 
exist, the seroprevalence of EGA was 3.8% and up to 17.6%, respectively (18). 
Limitations exist for seroprevalence studies. A. phagocytophilum strains vary in their 
pathogenicity between different hosts and some strains are non-pathogenic. Infection with 
non-pathogenic strains of A. phagocytophilum may therefore induce  seroconversion even 
though clinical disease does not occur  (12). As stated above, currently recommended IFA 
tests cannot differentiate between antibodies produced against specific strains.   
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1.3 Borrelia burgdorferi infection 
1.3.1. Etiology 
Lyme disease, or Lyme borreliosis (LB), is a multisystemic tick-borne disease caused by 
the spirochetes of the B. burgdorferi sensu lato complex. Lyme borreliosis is the most 
common vector-borne disease in North America and it is also endemic in parts of Europe and 
Asia (32–34). B. burgdorferi belongs to the family Spirochaetaceae, which also includes 
species within two genera - Leptospira and Treponema spp. These spirochetes have a 
wavelike body and flagella "tail" enclosed between the outer and inner cell membranes (34). 
The B. burgdorferi sensu lato complex includes a diverse group of bacteria that is 
distributed worldwide. Three genospecies, namely B. garnii, B. afzelii, and B. burgdorferi 
sensu stricto cause the majority of LB in Eurasia (34).  B.burgdorferi sensu stricto is the only 
species causing LB in the US (35,36). Lyme disease was first described in 1975 as an 
epidemic of arthritis among children in Lyme, Connecticut. The causative agent was 
discovered in 1982 by Burgdorfer et al., when it was isolated from infected Ixodes species 
(37). The disease affects humans and animals, which also serve as infection reservoirs.  
1.3.2. Hosts and vector ticks 
B. burgdorferi is transmitted to humans and animals by Ixodes species which feed on 
wildlife reservoir hosts, including birds, small mammals (mainly rodents) and large mammals. 
I. scapularis is the main vector in eastern and central North America, and I. pacificus is the 
main vector in western North America (38).  
The main reservoir hosts for B. burgdorferi in the US are white-footed mice on which 
larval and nymphal stages feed, some avian species (e.g. passerines) which mainly host 
nymphal stages, and the white-tailed deer, on which mainly adult but also nymphal stages 
feed.  White-footed mice, some other small mammals, and, rarely, avian species may remain 
infected and asymptomatic and serve as competent hosts. The white-tailed deer is an 
incompetent reservoir host, meaning that it does not maintain the infection long-term (34). 
1.3.3. Epidemiology 
The risk for infection with B. burgdorferi is multifactorial and varies with the distribution, 
density and prevalence of infection in the vector and host populations. In the US, most cases 
of Lyme borreliosis occur in the north-eastern and north central states (34). In Canada only 2 
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cases of Lyme borreliosis in horses were reported, in1988 from BC (8), where the vector I. 
pacificus is established (39). According to recent studies, the risk of exposure to Lyme 
borreliosis in Canada is increasing due to expansion of the geographic range of I. scapularis, 
which is enhanced by ongoing climate changes (38). Over the last decade, more 
geographically isolated populations of I. scapularis have become established in Southern 
Ontario, Southern Quebec, Southeastern Manitoba, Nova Scotia and New Brunswick (39). 
The reported prevalence of B. burgdorferi infection in I. scapularis in endemic areas in the 
north-eastern US is typically greater than 25% while it is typically less than 25% in south-
eastern Canada (38). The prevalence of B. burgdorferi infection in I. pacificus in endemic 
areas in BC is usually less than 10% (38). Thus, the risk for Lyme disease in areas where I. 
pacificus is the vector is likely lower than the risk in those areas where I. scapularis is the 
predominant vector (38).  
In non-endemic areas, there is still a risk for infection with B. burgdorferi as infected ticks 
can be introduced by migrating birds. These ticks are referred to as adventitious ticks. The 
prevalence of B. burgdorferi infection in ticks carried by migrating birds into Canada is 8 to 
15.4% (40). The risk of exposure to Lyme disease in non-endemic areas of Canadian 
provinces, which is mainly due to tick dispersion by migratory birds, is thus lower than in 
endemic areas, where the density and infection rate of the ticks is higher.   
In 2011, Ogden et al (41) reported that two additional Borrelia species, namely B. 
myiamotoi and B. kurtenbachii, were identified in I. scapularis ticks collected in a national 
surveillance program extending from Alberta to Newfoundland between 2005 and 2007.  B. 
kurtenbachii was identified as an entirely new species whereas B. myiamotoi had been 
previously reported from Connecticut (42). The pathogenicity and clinical relevance of these 
Borrelia species is unknown; however, they may need to be considered when investigating 
tick-borne diseases in Canada.   
Analysis of B. burgdorferi DNA obtained from infected ticks collected in surveillance 
programs suggests that the genetic diversity of B. burgdorferi strains in eastern and central 
Canada is similar to that in the US (34). This indicates that established populations of the 
vector I. scapularis were originally introduced to Canada from the north-eastern US.  
While introduction of the Ixodes vector from the US into Canada is progressing, it appears 
that establishment of Lyme borreliosis in Canada is lagging behind the establishment of tick 
vector populations. This is likely due to dilution of the infection in these populations. Dilution 
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refers to a decrease in prevalence of the pathogen within a vector population, which is due to 
either an increase in naïve vector populations, an increase in the non-competent host 
population (e.g. deer), a decrease in the competent and infected host population, an increase in 
the non-infected competent host population or a combination of several of these factors  
(39,41).  
1.3.4. Pathogenesis 
Genes encoding lipoproteins account for a significant portion of the B. burgdorferi genome 
and these genes show different expression levels in culture, in the vector tick and in the 
mammalian host (34). The outer surface protein A (Osp A) is expressed in culture and in the 
unfed tick gut to mediate attachment of the spirochete, whereas Osp B is expressed in host 
tissue and in culture and Osp C is expressed only when the spirochete is transferred to a 
mammalian host (34,43). Osp C is expressed early in the infection and is linked to 
invasiveness of B. burgdorferi, whereas Osp F is expressed later, during chronic infection. 
While the host tick is feeding, typically for 24-72 hours, the spirochetes  replicate in the 
mid-gut of the tick and move to its salivary gland (36). During this period, the spirochetes 
down-regulate expression of Osp A and up-regulate expression of Osp C. The spirochetes are 
transmitted after moving from the mid-gut of the feeding tick to its salivary gland due to 
influx of blood and an increase in temperature. This is the time when the spirochetes are 
metabolically active and express Osp C (43). 
A lipoprotein named variable major protein-like sequence expressed (Vls E) is required for 
persistence of B. burgdorferi infection in the competent mammalian host and is important for 
immune response evasion by modulation of the bacterial gene expression (34,43). Although 
the B. burgdorferi genome encodes for a large variety of lipoproteins, a limited number is 
expressed at any given time of infection of a mammalian host, reducing the number of 
potential targets for the immune response. The early antibody response against Osp C 
provokes down-regulation of Osp C expression, enabling evasion of the antibody response. 
Migration within connective tissue may further protect the organism from the host’s humoral 
response (43,44). Cytolytic activity attributed to Borrelia may explain how B. burgdorferi 
escapes macrophages lysosomal compartmentalization (43).  
Pathogenicity of B. burgdorferi inside the mammalian host involves utilization of  host 
proteases in order to traverse extracellular tissues (36). B. burgdorferi infection in mammalian 
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hosts involves migration, adhesion and immune evasion of the pathogen. The typical red 
circular skin lesion ("erythema migrans") at the site of the tick bite is the result of an 
interaction between the spirochete and the host’s immune response. Lymphocytes, dendritic 
cells, macrophages and plasma cells, all producing pro-inflammatory mediators, are seen on 
histology of these lesions (36). The organism may be found in blood during the very short 
bacteremia, cerebrospinal fluid, heart, retina, brain and meninges, muscle, bone, spleen and 
liver, accounting for the multiple symptoms associated with the infection (34,36,43). 
However, the fact that many infected hosts remain asymptomatic indicates that the clinical 
picture is determined by the interaction between the spirochete and host and not by infection 
with B. burgdorferi alone (36).  
1.3.5. Clinical disease in horses  
The clinical picture of Lyme borreliosis in horses is variable and includes arthritis, 
lameness, muscle tenderness, anterior uveitis, encephalitis, abortion, low grade fever and 
lethargy (43). Persistence of clinical signs associated with synovitis is attributed to an auto- 
immune cross-reactivity response to B. burgdorferi DNA. This means that antibodies against 
B. burgdorferi may attack synovial membrane components, causing progressive arthritic 
lesion (43). The variation in clinical signs may be associated with variation in the individual 
immune response or co-infection with other pathogens, e.g. A. phagocytophilum, which is 
transmitted by the same vector (44,45). 
Intravenous oxytetracycline and per oral doxycycline are commonly used for treatment of  
Lyme disease in horses (44). Oxytetracycline, possibly due to its higher blood and tissue 
concentration, showed better therapeutic results than doxycycline in experimentally infected 
ponies (46). The same observations were recorded in naturally infected horses (44). Early 
diagnosis and treatment initiation are preferable (44).  
Similar to EGA, the key factor in the prevention of Lyme borreliosis is avoidance of 
exposure to the vector. Although a variety of canine vaccines using the Osp A and Osp C 
antigen are commercially available (47,48) and are anecdotally used in an off-label fashion by 
some horse owners in the US, the efficacy of the vaccine in horses has not been reported. 
Currently, there are no commercially available vaccines for prevention of Lyme disease in 
horses.   
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1.3.6. Currently recommended diagnostic tests 
Diagnosis of Lyme disease is challenging. The diagnosis is typically made by taking into 
account a history of tick infestation in endemic areas, manifestation of typical clinical signs 
and serologic evidence of infection. Erythema migrans, which is pathognomonic for Lyme 
disease in humans, is not a characteristic finding in horses (43,44). With lameness being the 
most common clinical sign in infected horses, a variety of differential diagnoses need to be 
ruled out systematically (43,49,50).  
Interpretation of serologic tests for B. burgdorferi infection is challenging. The ELISA and 
IFA are considered sensitive tests for detecting anti- B. burgdorferi immunoglobulins in 
horses, with the ELISA reported to detect relatively more seropositive horses (43). Due to a 
relative low specificity of these tests, a two-tier approach has been developed, and is similar 
to the recommended serodiagnostic approach to Lyme disease in humans. Initial screening 
with a sensitive technique (i.e. ELISA or IFA) is followed, if positive, with a more specific 
Western Blot (WB) to detect antibodies to specific B. burgdorferi antigens (43,51). Due to the 
slow multiplication of the spirochete, a detectable antibody response may take 3-8 weeks to 
develop, and the sensitivity of combined tests may be low in the first few weeks of infection 
(43,51). As many seropositive horses are clinically normal, a single positive serologic test 
result is not sufficient to differentiate active infection from  exposure and repeating the test 
after 3 weeks is recommended (43). If the horse was acutely infected, the second titer is 
expected to be higher, whereas the titer of a previously exposed horse may wane or stay 
similar in a repeated test, but will not increase.  
The SNAP® 4Dx® ELISA and SNAP® 4Dx® Plus ELISA (IDEXX Laboratories) use a 
synthetic C6 peptide resembling the invariable region of the membrane protein VlsE to detect 
antibodies against B. burgdorferi. Anti-C6 antibodies are expressed during natural B. 
burgdorferi infection and can therefore distinguish natural infection from an antibody 
response to vaccination, which results in production of anti-OspA antibodies but not anti-C6 
antibodies (52). According to a study evaluating the test’s performance in serum samples 
from 164 horses (28), sensitivity and specificity of the SNAP® 4Dx® ELISA relative to a 
commercially available Western Blot kit were 100% and 95%, respectively. Samples for this 
study were obtained from presumed infected horses, i.e. horses that had previously been 
tested for Lyme borreliosis, and presumed non-infected horses, i.e. horses that resided in a 
non-endemic area in the US. Lack of gold standard to confirm positive cases and possible 
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cross reactivity were not addressed in this study and may be a limitation in this study. The 
reported sensitivity and specificity of the SNAP® 4Dx® ELISA in horses experimentally 
infected with B. burgdorferi was 63% and 100% respectively (29).  
The Equine Lyme multiplex assay is based on antigen-labeled fluorescent beads. The 
multiplex assay detects antibodies against three B. burgdorferi antigens, namely Osp A, Osp 
C and Osp F, in horse serum (48). The use of these antigens enables earlier diagnosis - as 
early as 2-3 weeks post infection (53,54) - compared to the IFA or ELISA with WB 
confirmation, where the earliest time of antibody detection averages 5 to 6 weeks post 
infection. The Lyme multiplex assay is quantitative and, according to the manufacturer’s 
website information (55), the antibody profile allows an assessment of the stage of infection, 
vaccination status and treatment success in horses. In addition, the multiplex assay agreed 
with C6 ELISA testing of serum samples from  infected and non-infected horses (48,54).  
In experimentally infected ponies, culture of B. burgdorferi has been reported from skin 
biopsy samples of tick bite sites, and post mortem from joint capsules, muscles and lymph 
nodes (56). Manion et al. (57) reported isolation of viable spirochetes from the urine of two 
clinically normal horses. Molecular detection of B. burgdorferi DNA by PCR from synovial 
tissue or skin biopsy samples may improve sensitivity and specificity of detecting active B. 
burgdorferi infection (43,44). Information about possible cross-reactivity affecting serologic 
tests for LB in horses is lacking, however, the potential for cross-reactivity should be 
considered.  
1.3.7. Relationship between seroprevalence and clinical disease 
Although the seroprevalence of Lyme borreliosis in horses in some endemic areas in the 
northeastern United States may reach 60% (45,58–60), clinical disease associated with B. 
burgdorferi infection in horses is uncommon. Approximately 10% of seropositive horses 
develop clinical disease (45,58).  
1.4 Ixodes  
The family Ixodidae is the largest tick family contains approximately 650 tick species (14). 
Ixodid ticks are characterized by a dorsal plate called scutum. With 245 species, the genus 
Ixodes is the largest in the family Ixodidae (14). The Ixodes ricinus complex comprises 14 
species and includes I. scapularis and I. pacificus in North America, I. ricinus in Europe and 
I. persulactus in eastern Europe and Asia (14,61). The species in the I. ricinus complex are 
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responsible for many Ixodes borne diseases in humans and animals. The ticks serve as a 
primary vector for B. burgdorferi and A. phagocytophilum infection in humans and animals 
and Babesia microti infection in humans (14).  
1.4.1. Ixodes scapularis and Ixodes pacificus 
I. scapularis is morphologically similar to I. pacificus (62,63); however, the species differ 
in their geographic distribution and feeding preferences. I. scapularis is found in the 
northeastern and midwestern US while I. pacificus is found on the west coast. In Canada, 
established populations of I. scapularis are known in southern Ontario and Quebec, Nova 
Scotia New Brunswick and southeastern Manitoba (38,39,64). Established populations of I. 
pacificus are distributed in southern British Columbia (38,39).   
1.4.2. Life cycle 
I. scapularis and I. pacificus are three-host ticks and each tick stage feeds on a different 
host. The life cycle of Ixodes involves four life stages, namely the egg, larva, nymph and 
adult, and usually spans two years (3). Tick activity differs dramatically with season and life 
stage (14) and in colder areas, the life cycle may take up to 3 years to complete (3).   
The life cycle of I. scapularis has been described (Division of Vector Borne Infectious 
Disease, Atlanta, GA) and is shown in Figure 1.The larva hatches from the egg in the summer 
and feeds on small vertebrates, primarily the white-footed mouse, for 3-5 days. Larvae may 
also feed on birds or reptiles. The engorged larva then drops off the host to the ground, 
overwinters and molts to the nymph stage in the early spring. The nymph feeds on the second 
host (small mammals or birds) for 3 to 4 days, drops off and stays dormant until late summer 
or early fall, at which time it molts to an adult tic . The adult tic  is active in the fall and 
winter months as long as ambient temperature e ceeds 0 C. Adult female and male tic s see  
out a larger vertebrate host to feed and mate on, the female feeding for 5 to7 days before 
dropping off, overwintering and laying eggs in the spring before it dies. The male scarcely 
feeds and can stay on the host for a longer time period before dying.  
Unlike I. scapularis larvae, the larvae and nymphs of I. pacificus prefer to feed on lizards 
(65). In general, both I. scapularis and I. pacificus are considered to have a "non-specific" 
feeding habit, meaning that they not only feed on their natural reservoir hosts but may also 
feed on humans (14) and horses (43,66).  
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Figure 1.1 Ixodes scapularis life cycle adapted with permission from the Center for     
Disease Control (Division of Vector Borne Infectious Disease, Atlanta, GA) 
1.4.3. Pathogen transmission  
A tick is considered a vector for a pathogen if the tick feeds on a vertebrate host, is able to 
acquire the pathogen during a blood meal, maintains the pathogen through one or more life 
stages, and  transmits the pathogen  to another host during the next blood meal (61). 
Transovarial transmission of A. phagocytophilum and B. burgdorferi infection is considered 
insignificant in Ixodes. Larvae are therefore typically not infected upon hatching but may get 
infected when feeding on a reservoir host, and may transmit infection in the subsequent blood 
meal, as a nymph. Infected nymphs will molt to infected adults but adult females will not 
transmit the infection to the eggs (14). 
The asynchronous seasonal activity of nymph and larval stages of I. scapularis appears to 
play a major role in maintaining efficient transmission cycles of B. burgdorferi (67). Infected 
nymphs are active in the spring and early summer and transmit the infection to rodents. 
Infected rodents transmit the infection to non-infected larvae, which are active in mid- to late 
summer. Larvae molt to infected nymphs in the following spring and account for a high 
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prevalence of B. burgdorferi infection in questing nymphs (67). Lindsay's study of duration of 
B. burgdorferi infection in white-footed mice suggested that efficient transmission of B. 
burgdorferi between different stages of the ticks is possible due to occurrence of co-feeding, 
which denotes the feeding of two tick stages on the same host (68). During co-feeding, 
infected nymphs feed between May and July and transmit infection to white-footed mice 
which remain infective for 3 weeks. The mice then transmit the infection to un-infected 
overwintered tick larvae that feed during June and July (68,69). 
Compared to a low transmission rate of A. phagocytophilum, the transmission rate of most 
strains of B. burgdorferi from acutely infected rodents to ticks is considered high (>50%)(67). 
While the majority of B. burgdorferi species are transmitted with high efficiency from 
infected white-footed mice throughout their entire life span, some A. phagocytophilum strains 
may have a short duration of infection in rodents (67). For a pathogen to survive, the time in 
which a rodent is infective must be consistent with the seasonal activity of larval and nymph 
stages and with the gap between their activity periods (67). 
In laboratory settings, I. pacificus nymphs were more competent vectors than I. scapularis 
nymphs for A. phagocytophilum, meaning they were better able to maintain the infection.  
However, the reported transmission efficiency for strains of A. phagocytophilum in these tick 
species does not necessarily correlate with the known geographic differences in disease 
prevalence. The fact that A. phagocytophilum prevalence in I. pacificus is considerably lower 
than that in I. scapularis in nature, alongside the finding that fewer human granulocytic 
anaplasmosis cases are reported in the western US, suggests that location-specific prevalence 
of A. phagocytophilum infection may involve other factors besides strain transmissibility and 
vector competence. Suggested factors include differences in host tropism and pathogenicity 
(65).  
1.4.4. Prevalence of tick infection and potential for co-infection  
1.4.4.1. United States  
In the northeastern and midwestern US, the frequency of B. burgdorferi infection in I. 
scapularis ranges from  35 to 72%, and that of A. phagocytophilum infection ranges from 1 to 
16% (20). The reported prevalence of infection with B. burgdorferi and A. phagocytophilum 
in  I. pacificus ticks in the western US is 1.6 - 6.5% and 4.7%, respectively (66,70,71).  
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1.4.4.2. Canada 
The reported prevalence of B. burgdorferi infection in I. scapularis collected by passive 
and active surveillance in  ON and QC ranges from 4.9 to 13.2% (39,64). Interestingly, the 
prevalence of B. burgdorferi infection in I. scapularis collected from birds migrating 
northward from the US into Canada was 8 to 15.4% (40). The prevalence of A. 
phagocytophilum infection in I. scapularis ticks in eastern Canada was 1.4%, similar to the 
infection prevalence in ticks that were collected from migrating birds in the same study (40). 
These data suggest that invasion of tick-borne pathogens into tick populations in Canada is 
likely due to infected ticks arriving on migrating birds from the US. 
1.4.4.3. Potential for co-infection 
Generally, co-infection with A. phagocytophilum and B. burgdorferi is common and 
geographically widespread, both in the tick vector and in the vertebrate hosts (66). However, 
the types of co-infecting organisms within the tick vary. The most prevalent (61%) dual 
infection reported by Steiner et al. (20) was that of B. burgdorferi and the Ixodes- specific 
Rickettsial endosymbiotic organisms. Other dual infections were less common. Co-infection 
with A. phagocytophilum and B. burgdorferi in nymphal or adult I. scapularis may be 
acquired simultaneously from a co-infected host or in two consecutive feedings (14,20). The 
reported prevalence of co-infection with A. phagocytophilum and B. burgdorferi in I. 
scapularis ticks from areas endemic for Lyme disease reached 28% in the north-eastern US 
and 2% in the midwestern US (14). In northern California, the reported prevalence of co-
infection with A. phagocytophilum and B. burgdorferi in I. pacificus ticks was approximately 
1% (14). Triple co-infection, e.g. with A. phagocytophilum,  B. burgdorferi and B. microti, 
was even less common (14).  
Levin and Fish (72) demonstrated that the presence of A. phagocytophilum and B. 
burgdorferi, respectively, in I. scapularis does not prevent the tick from acquiring or 
transmitting the other organism to a white-footed mouse. On the other hand, primary infection 
with either A. phagocytophilum or B. burgdorferi in immune-competent mice appears to 
inhibit acquisition and transmission of the second agent, suggesting interference between the 
organisms in vertebrates. The different interaction between the agents  in the vertebrate host is 
likely mediated by the host’s immune response (73).  
The prevalence of co-infection with A. phagocytophilum and B. burgdorferi in non-human 
mammalian hosts varies with geographic location, season and type of host (14). Results of 
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antibody detection and molecular methods (PCR) indicated that prevalence of co-infection in 
white-footed mice in Connecticut was approximately 50% but varied between different areas 
in the state (14). In the Western US, dual infection with A. phagocytophilum and B. 
burgdorferi was also detected in other mammals such as deer mice and Mexican wood rats 
(14). In experimental dual infection studies in animals, an increase in severity of Lyme 
borreliosis was observed (14). This suggests impaired immune function in animals infected 
with A. phagocytophilum. In human patients, co-infection with  A. phagocytophilum and B. 
burgdorferi appears to be associated with more severe clinical signs of longer duration, or 
with  persistence of both infections (74).  
1.4.5. Current geographic range of the vectors in Canada 
Ixodes are distributed throughout woodland and grass lands. The risk of I. scapularis-borne 
diseases is emerging in Canada and is following the northward pattern of geographic 
expansion of the tick vectors that was seen in the northeastern and midwestern US (75). The 
influences determining the geographic distribution and abundance of Ixodes vary and include 
the presence of woodland and bushy habitats, presence and density of suitable hosts for the 
different life stages, and presence of suitable environmental temperatures and moisture 
conditions for tick  development and activity (14,76). These factors affect the survival rate of 
ticks and the establishment of new tick populations (77). An established tick population is 
defined as a population of reproducing ticks, meaning that all life stages can be found in at 
least two subsequent years (78). 
The geographic distribution of I. scapularis in Canada appears to originate from two foci 
in the northeastern and Midwest US (79). The tick was introduced into Canada due to local 
host migration and distant migration on migratory birds (39,40,79). The geographic expansion 
of the vector is likely the reason for observing an increased incidence of Lyme disease in 
Canada in recent years (79). Up to 1997, a single known established population of I. 
scapularis ticks in Canada was present at Long Point, ON. By 2008, the number of 
established I. scapularis populations had risen to 13, and included those at the Great Lakes 
shores in ON, Wood Lake shore in MB and the coast of NS (40,79). Most of the known 
Canadian I. scapularis populations are geographically isolated from one another and are 
therefore less likely to result from local migration of local hosts (40). However there is also 
evidence suggesting establishment of populations in a wider area of QC, similar to the pattern 
of expansion observed in the US (39).  
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1.4.6. Potential causes of range expansion 
The three major factors contributing to the current and anticipated further range expansion 
of tick habitats within Canada are local spread, distant migration and climate changes (75,79). 
It is suggested that for a new population of ticks to be established, a threshold number of ticks 
is required (76,77). 
1.4.6.1. Local spread  
The white-tailed deer constitutes the major source of a blood meal for the gravid female I. 
scapularis in the eastern and north central regions of the US. As the primary host for the 
reproducing stage, which will produce thousands of eggs, the deer’s presence is essential for 
the establishment and spread of an I. scapularis population (80). Although deer are a non-
competent reservoir for Lyme disease and cannot transmit the infection to feeding ticks, 
increased incidence of Lyme borreliosis in humans in the US was associated with the 
presence of deer (80). Resurgence of the white-tailed deer population over the past decades 
also contributed to the expansion of the geographic range of I. scapularis populations in much 
of the eastern United States (14). Although not quantified, the rapid increase in the number of 
reported human cases of Lyme borreliosis in the US since the early 1980s is associated with 
the dramatic growth of the deer population in the 20th century (80). Deer exclusion studies, 
which involve deliberate elimination of individuals in the deer population in certain areas, 
have shown a reduction in tick abundance in those areas where deer populations were reduced 
(80). An increase in residential deer sightings was associated with an increase in clinical cases 
of Lyme disease in humans  and an increase in the number of dogs testing seropositive for 
Lyme disease (80). In addition to its importance for Lyme Disease, the white-tailed deer is 
also one of the main reservoirs for A. phagocytophilum variants in the US (16). Deer are 
usually infected with the A. phagocytophilum Var - 1 strains, which are non-human strains 
(10). The general increase in tick abundance is suggested as the cause for increased incidence 
of Lyme in areas with high deer density, due to increased abundance of the ticks. 
As discussed earlier, geographically isolated populations of Ixodes occur on the southeast 
shore areas of MB, ON and the coast of NS. These populations are therefore less likely to 
have resulted from range expansion of local hosts (40). However, tick migration from 
established Canadian populations via local host migration can contribute to the establishment 
of new tick populations in Canada. Deer population density is suitable and is of great 
importance in that deer can carry high numbers of ticks, including gravid females, to distant 
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areas (75). Considering that climate changes are likely to favor reproduction of the migrating 
ticks, this may be an important route for establishment of new populations of the vector in 
Canada. Success of tick invasion with regard to host abundance, host diversity and geographic 
variation in Canada needs to be investigated further (75) 
1.4.6.2. Migrating birds  
Migratory passerines are hosts for I. scapularis in North America and may carry I. 
scapularis northward into Canada during their spring migration (40). These migrating birds 
mostly carry nymphs and may disperse I. scapularis over a considerable distance within 
Canada. The ticks that are carried by migrating birds and dropped in distant areas are called 
adventitious ticks. Adventitious nymphs may survive through molting, and infected adult 
ticks may then transmit tick-borne infections to the next host they quest (40,79). However, the 
risk for encountering these infected ticks is likely low due to their relatively lower density 
compared to the density of reproducing populations. Adult ticks are also in general less likely 
to transmit disease to humans due to their larger size and ease of identification and removal 
by humans (40). It is possible that infected adventitious ticks pose a greater risk for other 
large mammals such as horses, which are less likely to remove them.  
1.4.6.3. Climate changes  
In laboratory studies, inter-stadial developmental periods of I. scapularis (i.e. the length of 
time between molts) decreased significantly with increasing ambient temperature (81). Inter-
stadial development time of ixodid ticks usually decreases with increasing ambient 
temperatures; however, onset and termination of the dormant stage is complex and relates also 
to an increase in day length, exposure to extreme ambient temperatures and humidity levels. 
Variation of ambient temperature within narrow ranges (e.g. within 5-100 C for the interval to 
first egg production and within 10-200C for the interval from egg deposition to hatching of 
larvae) appears to produce significant variation in developmental rates. Above 200C, a further 
increase in ambient temperature appears to produce smaller changes in development (81). 
Incubation temperatures > 300C had a detrimental effect on developing ticks (81). Climate 
change is anticipated to increase the number of days with an ambient temperature > 00C and 
thus may enhance the tic s’ survival and reproduction efficiency (40). Anticipated climate 
changes may therefore lead both to geographic expansion of existing populations and to an 
increased survival of new populations.  
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A dynamic population model of I. scapularis was developed by Ogden et al. (77) in order 
to simulate the effects of temperature change on tick survival and seasonality. The model 
considered the effects of changes in rodent and deer density, meteorological data from 
stations near endemic populations of I. scapularis, humidity and protection by litter layer. 
Increased tick die-out due to a steady increase in mortality of all life stages was associated 
with decreasing ambient temperatures. Conversely, maximum numbers of ticks in self-
sustaining balanced populations were associated with the mean annual number of degree days 
  0 (77). The threshold for establishment of new Ixodes populations was mapped and 
indicated that there are regions in Canada which currently experience temperature conditions 
suitable for I. scapularis establishment, and that these are more extensive than the currently 
recognized distribution of I. scapularis populations (77). These areas also overlap with the 
areas of highest human population density in southeastern Canada. Environmental conditions 
were found to be suitable for tick establishment in Southern AB, SK and MB where I. 
scapularis are mostly introduced by migrating birds to date (77). The tick population trends 
shown in the model suggest that increasing ambient temperatures with anticipated climate 
change will expand the northern and western ranges of I. scapularis. The model also 
demonstrated that the tick population in NS has become established where unfavorable 
temperatures exist, suggesting that tick mortality and host finding rates are optimal in the 
Maritimes (77).  
In a subsequent study, a tick population model based on two global climate models 
predicted that tick abundance will almost double by 2020 and that threshold numbers needed 
to establish new tick populations will decrease during the next decades (76). The degree of 
range expansion and survival of new populations are anticipated to be evident in the next two 
decades (76).  
Risk maps for predicting the expansion of I. scapularis habitats in Canada were created 
using a simple risk algorithm for new I. scapularis populations to occur. The maps include 
slow and fast scenarios and both indicate an increased risk of I. scapularis establishment in 
currently low-risk areas, as well as northward and westward expansion of existing endemic I. 
scapularis populations (82).  
Surveillance data from the Public Health Agency of Canada support an increase in the 
geographic range and number of established I. scapularis populations in much of Southern 
Canada (Public Health Agency of Canada, http://www.phac-aspc.gc.ca/id-mi/tickinfo-
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eng.php, last accessed on September 21, 2013). Established populations have been reported in 
NB, QC, NS, Ontario and MB. Established populations of I. pacificus were reported in 
southern BC.  
1.4.7. Relationship between endemic tick populations and endemic tick-borne disease 
As defined by Health Canada, endemic areas for Lyme disease, in which the risk for Lyme 
disease is greatest, are those areas where populations of the tick vector have been established 
and where there is evidence that the established tick populations are transmitting Lyme 
disease (78). Based on active surveillance data, the Public Health Agency of Canada reported 
that established populations of I. scapularis which are endemic for Lyme disease occur in 
limited areas in Canada (Public Health Agency of Canada http://www.phac-aspc.gc.ca/id-
mi/tickinfo-eng.php, last accessed on September 21, 2013). The Public Health Agency of 
Canada currently reports six Lyme endemic areas in NS, two in NB, five in QC, seven in ON 
and three in MB. Three more areas in MB are reported as suspected Lyme endemic areas. 
Established populations of I. pacificus are known to occur in some areas of southern BC 
(mainly Vancouver Island) and others are suspected over a wider region. To date, Lyme 
borreliosis is reportedly not endemic in BC. 
Migrating birds could be significant in the establishment of endemic transmission cycles of 
I. scapularis-borne pathogens by introducing infected ticks to non-endemic areas or by 
increasing the pathogen load in endemic areas. Ogden et al. (40) estimated that the prevalence 
of tick infestation  in migrating birds was 2.2% and infestation density on average was 1.6 
ticks per bird. They concluded that migrating birds account for the dispersion of 50 to 175 
million I. scapularis ticks across Canada each spring. In the same study, 15.4% and 1.4% of I. 
scapularis nymphs collected from migrating birds were PCR positive for B. burgdorferi and 
A. phagocytophilum, respectively. This prevalence of A. phagocytophilum infection  was 
consistent with that reported in I. scapularis nymphs in the northeastern US (40). Birds are 
mostly zooprophylactic for B. burgdorferi, meaning they reduce the presence of infection in 
the ticks they carry. This was established based on spring bird observations in and east of 
Long Point, ON (40). The prevalence of B. burgdorferi infection in subset of nymphs 
collected from birds that migrated via the east coast (8.3%) was significantly lower than that 
of B. burgdorferi infection in questing nymphs in the north eastern US (>30%) (40). 
A subsequent study predicting the rate of B. burgdorferi invasion into established I. 
scapularis tick populations in Canada used a simulation model of I. scapularis populations 
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and B. burgdorferi transmission (64). The simulation model identified that the number of 
introduced ticks, both infected and non-infected, was the most important factor in determining 
the speed of B. burgdorferi invasion after I. scapularis has been established. The model 
predicted greater numbers of introduced infected nymphs in central Canada versus eastern 
Canada (64). 
Seasonal activity of the immature stages of I. scapularis differs between the north-eastern 
and midwestern US, which likely affects the risk of introducing tick-borne diseases through 
adventitious ticks in Canada. Larval and nymphal activity is synchronous in the Midwest 
whereas in the northeast, nymphs are active in the spring and larvae are active in the summer 
(64). Northward migrating birds therefore disperse both active larvae and nymphs from the 
midwestern US to central Canada in the spring, whereas tick dispersion from the northeastern 
US into eastern Canada is composed mainly of nymphs with only a non-significant number of 
larvae introduced. The higher number of infected larvae introduced into central Canada results 
in a higher number of infected nymphs after molting, which then feed on competent small 
mammal hosts that can maintain and are able to transmit infection. Introduced infected 
nymphs, on the other hand, molt into adult ticks after leaving the migratory bird host, and 
these adults typically feed on a non-competent large mammal host that is unable to further 
transmit the infection. Ogden et al. therefore hypothesized that a five-year gap will occur 
between tick invasion and B. burgdorferi invasion into eastern Canada compared to a much 
shorter gap in central Canada (64). 
The term “dilution effect” refers to the inhibition of pathogen transmission cycles which 
occurs when non-competent host species are added to host populations, making the pathogen 
less abundant and less likely to persist (83). Thus the number of new infections and the 
overall reproduction ability of the pathogen will be reduced (83). Increased biodiversity, 
increased host species richness and evenness between competent hosts, which are typically 
more abundant, and non-competent hosts should result in reduced pathogen abundance 
(83,84).  
The prevalence of B. burgdorferi infection in adult ticks collected through passive 
surveillance in QC before 2004 was 13.2% (85), similar to the prevalence reported in  
engorged I. scapularis  nymphs collected from northward migrating birds (15.4%) (40). The 
authors indicated that, after 2004, the number of submitted ticks increased each year, which 
was mostly due to increased submissions from areas close to the US border. During the same 
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time period, the prevalence of B. burgdorferi infection in the submitted ticks declined to 4.9% 
(39). This finding was accompanied by active surveillance studies in southern QC (June-
October, 2007-2008), in which prevalence of B. burgdorferi infection in many emerging I. 
scapularis populations was either undetectable or was low at most sites (7.7%) (39). These 
findings suggest that the establishment of  I. scapularis populations free of B. burgdorferi 
may dilute the infection prevalence in the adventitious ticks dispersed from the US, and will 
increase the overall proportion of uninfected ticks in the environment (39).  
As hereby described, expansion of the geographic range of Ixodes is multifactorial and 
influenced by environmental conditions, ongoing processes, as well as limitation factors. 
However, the emergence of the tick is continuously evident in recent decades and the concern 
over Ixodes borne diseases is therefore increased.  
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1.5.   Hypotheses and Objectives 
The first goal in this work was to characterize the current level of horse exposure to EGA 
and LB in Canada. This work is described in chapter 2. The terms seropositive, seronegative 
and seroprevalence in this and all other studies refer to the presence (or absence) of antibodies 
in a serum sample. The second goal was to understand whether a point-of-care ELISA is 
comparable to currently recommended serologic tests for EGA and LB in horses. The 
hypotheses and objectives for this chapter are as follows:    
Hypothesis 1: That based on a point-of-care ELISA, seroprevalence of EGA and equine 
LB in SK, MB and ON is low. 
Objective 1: To estimate the seroprevalence of EGA and LB in horses in SK, MB and 
ON by testing convenience serum samples submitted to provincial diagnostic laboratories 
using a point-of-care ELISA. 
Hypothesis 2: That the assessment of a sample as seropositive or seronegative for EGA 
and LB does not differ between a point-of-care ELISA and laboratory-based serologic tests. 
Objectives 2.1: To evaluate agreement between a point-of-care ELISA and laboratory-
based IFA for EGA based on an inter-rater agreement statistic and a comparison of the 
proportion of positive tests, using convenience serum samples. 
Objective 2.2: To evaluate agreement between a point-of-care ELISA and laboratory-
based ELISA/WB combination for LB based on an inter-rater agreement statistic and a 
comparison of the proportion of positive tests, using convenience serum samples. 
As agreement between serologic tests varied in the first study, agreement was further 
investigated between all available serologic tests for EGA and LB in chapter 3. The goal of 
this work was to establish whether different serologic tests will result in the same assessment 
of a sample as seropositive or seronegative. The hypotheses and objectives for this chapter are 
as follows:  
Hypothesis 3: That the assessment of a sample as seropositive or seronegative for EGA 
or LB, respectively, is independent of the specific testing method used.  
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Objective 3.1: To evaluate agreement among a point-of-care ELISA and two laboratory-
based IFAs for EGA based on an inter-rater agreement statistic and a comparison of the 
proportion of positive tests, using convenience serum samples. 
Objective 3.2: To evaluate agreement among a point-of-care ELISA, laboratory-based 
IFA, laboratory-based ELISA/WB combination and laboratory-based Lyme multiplex assay 
for LB based on an inter-rater agreement statistic and a comparison of the proportion of 
positive tests, using convenience serum samples. 
The goal of the third study was to better understand the risk for exposure of horses in 
Canada to EGA and LB. Management factors were compared between horses that tested 
seropositive or seronegative to EGA and LB in chapters 2 and 3. The hypothesis and 
objectives for this chapter are as follows: 
Hypothesis 4: That the signalment, management and clinical history do not differ 
between horses that tested seropositive or seronegative for EGA or LB, respectively. 
Objective 4.1: To obtain information regarding signalment, management and clinical 
history for horses whose serum samples were tested for EGA and LB in previous studies, 
using mail-out surveys. 
Objective 4.2: To compare the signalment, pasture access, tick infestation and tick-borne 
disease history, travel history and Lyme disease vaccination status between horses testing 
seropositive or seronegative for EGA or LB, respectively. 
Finally, as data concerning the ticks infesting horses in SK are not available, describing 
the ticks that may be found on horses in SK was the goal of the fourth study. This study is 
described in chapter 5. The hypothesis and objective for this chapter are as follows:  
Hypothesis 5: That tick species known to be established in SK, as well as adventitious 
tick species can be found on horses in SK.  
Objective 5: To describe the species, sex, life stage, state of engorgement and geographic 
location of acquisition of ticks submitted from horses in SK over a 2-year period.  
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Transition to chapter 2 
Horses may be exposed to the causative agents of equine granulocytic anaplasmosis and 
Lyme borreliosis when infested by the vector ticks, I. scapularis and I. pacificus, which are 
the most common competent vectors transmitting the pathogens to horses in North America 
(16,18,43,50,86).  
As discussed earlier in the thesis, diagnosed cases of EGA and LB have been reported in 
Canada from provinces with and without established populations of the vector. However, the 
prevalence of tick-borne infections in horses in Canada has not been reported to date. Thus, 
there is a need to better understand the prevalence of tick-borne infections and the risk of 
exposure to the vectors and the causative organisms in horses in Canada. 
The aim of the first study was to estimate the seroprevalence of EGA and LB in horses in 
Canada.  A point-of-care ELISA was used to screen equine serum samples from 3 provinces, 
namely ON, MB and SK. The hypotheses were that based on a point-of-care ELISA, the 
seroprevalence of EGA and LB SK, MB and ON is currently low, and that the assessment of a 
sample as seropositive or seronegative for EGA and LB does not differ between a point-of-
care ELISA and laboratory-based serologic tests.  
The author of this thesis collaborated with Drs. K. Lohmann, H. Burgess, T. Epp and N. 
Chilton in planning the study, handling samples and reviewing the results and statistical 
analysis.  
The author of this thesis performed the testing for antibodies against A. phagocytophilum 
and B. burgdorferi using a point-of-care ELISA  it according to the manufacturer’s 
instructions. Selected samples were further re-tested at the Connecticut Veterinary Medical 
Diagnostic Laboratory. Recording of test results, data analysis and reporting of the results 
were performed by the author of the thesis. Results were presented as a research poster during 
the graduate student poster day at the Western College of Veterinary Medicine, University of 
Saskatchewan, SK (March 13,  2013) and at the ACVIM Forum, American College of 
Veterinary Internal Medicine, in Seattle, WA (June 12-15, 2013).  This chapter will be 
submitted for publication in the Canadian Veterinary Journal which will hold copyright. 
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2. SEROPREVALENCE OF EQUINE GRANULOCYTIC ANAPLASMOSIS AND   
      LYME BORRELIOSIS IN HORSES IN CANADA AS DETERMINED BY A  
      POINT-OF-CARE ELISA 
2.1  Abstract 
Equine granulocytic anaplasmosis (EGA) and Lyme borreliosis (LB) are tick-borne 
diseases transmitted by the Ixodes species. While Ixodes-borne diseases are an emerging 
concern in Canada, the risk of exposure to horses is poorly understood. A point-of-care 
ELISA for detection of antibodies against A. phagocytophilum and B. burgdorferi is licensed 
in dogs and reportedly accurate in horses. The objectives of the study reported here were to 
estimate the seroprevalence of EGA and LB in Saskatchewan (SK), Manitoba (MB) and 
Ontario (ON) and to investigate agreement between a point-of-care ELISA and laboratory-
based serologic tests.  
   Convenience serum samples obtained from veterinary diagnostic laboratories in SK 
(n=202), MB (n=140) and ON (n=34) were tested using the SNAP® 4Dx® ELISA (IDEXX 
Laboratories, Inc., Westbrook, ME) and a seroprevalence estimate with 95% confidence 
interval was reported overall and for each province. Seropositive samples for EGA (n=2) or 
LB (n=6) and two randomized subsets of seronegative samples (n=92 each) were re-tested by 
indirect immunofluorescence antibody assay (IFA) for EGA, or whole cell ELISA confirmed 
with Western Blot (WB) for LB, in a commercial veterinary diagnostic laboratory. Antibody 
titers ≥1:80 for IFA and ≥1:160 for whole cell ELISA (when WB confirmed) were considered 
positive. Agreement between the SNAP® 4Dx® ELISA and each laboratory-based serologic 
test was assessed by comparing the proportion of positive test results (McNemar’s test) and 
by inter-rater agreement testing (Kappa statistic). 
   Based on the SNAP® 4Dx® ELISA results, the overall seroprevalence of EGA was 0.53% 
(95% CI: 0.09 -2.12%) while the provincial seroprevalence was 0.49% (95% CI: 0.02-3.1%) 
in SK, 0.71% (95% CI: 0.03-4.5%) in MB and 0% (95% CI: 0-12.6%) in ON. Overall 
seroprevalence of LB was 1.6% (95% CI: 0.65-3.6%) while the provincial seroprevalence was 
0.49% (95% CI: 0.02-3.15%) in SK, 2.9% (95% CI: 0.96-7.15%) in MB and 2.94% (95% CI: 
0.15-17%) in ON. The proportion of positive results differed significantly between serologic 
tests for EGA but not between serologic tests for LB. For LB, test agreement was considered 
fair according to a Kappa value of 0.23 (95% CI: -0.03 - 0.50). 
29 
 
   Conclusions: While the SNAP® 4Dx® ELISA yielded expected seroprevalence estimates,  
test results failed to agree (for EGA) or showed only fair agreement (for LB) when the test 
was compared with laboratory-based serologic tests. This may be attributable to false positive 
(possibly due to cross-reactivity) or false negative test results. Agreement between the 
SNAP® 4Dx® ELISA and laboratory-based serologic tests in horses requires further 
investigation.  
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2.2 Introduction 
Granulocytic anaplasmosis is caused by Anaplasma phagocytophilum and has been 
reported in horses, dogs and humans in Canada (6–10). Equine granulocytic anaplasmosis 
(EGA) is characterized by fever, anorexia, depression and distal limb edema (10,16). The 
main hematological abnormalities are neutropenia and thrombocytopenia (24,87). Three case 
reports from British Columbia (BC) (4), Nova Scotia (NS) (5) and Saskatchewan (SK) (6), 
and one  report from New Brunswick (NB) (7) describe the occurrence of the disease in 
horses in Canada.  
Lyme borreliosis (LB) is caused by Borrelia burgdorferi and has been reported in horses, 
dogs and humans in Canada (8,38,88–91). Lyme borreliosis in horses is characterized by 
lameness, joint effusion, muscle tenderness, depression and generally decreased performance 
(43,44,50). Low-grade fever, laminitis or uveitis may also be present (44). While the disease 
has been reported in only two horses from BC to date (8), it is possible that cases are 
overlooked due to the rather non-specific clinical signs observed in horses.  
The blacklegged tick, Ixodes scapularis, and the Western blacklegged tick, Ixodes 
pacificus, are the principal vectors for EGA and LB in eastern and western Canada, 
respectively (88). Southern Quebec, southern Ontario (ON) and southeast MB are endemic for 
I. scapularis while a few areas in BC are reported to be endemic for I. pacificus (39). In 
Canada, presence of  A. phagocytophilum and B. burgdorferi in Ixodes and infections in 
humans and veterinary species  have been reported from areas with and without established 
populations of the vector ticks (4–6,38,64,89–94). Disease exposure in non-endemic areas is 
suggested to occur due to adventitious ticks, which are ticks that are carried into an area by 
migrating animals or humans. 
Risk maps for the emergence of the tick vector I. scapularis suggest that climate changes 
will accelerate range expansion of the vector in eastern and central Canada (82). Other 
contributing factors are local host migration and distant migration by birds migrating to 
Canada in the spring (40,76,77,82). Geographical range expansion predictions anticipate the 
emergence of new cases of LB in humans and animals in areas with and without established 
Ixodes populations (64,76,77,81). Studies focused on Borrelia phylogeographics, currently 
known endemic areas of Ixodes  in the US, and bird migration into Canada (including analysis 
of their parasitic infection status) indicate an association between the population pattern of I. 
scapularis in the US and its expansion within Canada (40,41,64,76,77,95). These studies 
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suggest that the risk for exposure to Ixodes-borne diseases is emerging in Canada. Hence, the 
risk for horse exposure in Canada, both in currently endemic and non-endemic areas, is 
expected to increase.  
The currently recommended diagnostic test to detect antibodies against A. 
phagocytophilum is the indirect immunofluorescence antibody assay (IFA) (27). Antibodies 
against B. burgdorferi in horses may be detected by IFA, ELISA confirmed with Western 
Blot (WB) or a Lyme multiplex assay using immunofluorescence beads (43,51,54). The 
presence of antibodies in blood may indicate active infection associated with active 
production of antibodies against the existing organism. However, the presence of antibodies 
may also indicate exposure and persistence of detectable antibody levels in the absence of 
active infection.  Antibodies to A. phagocytophilum may persist for up to 2 years in horses 
(25). 
A point-of-care SNAP® 4Dx® ELISA (IDEXX Laboratories, Westbrook, ME) is labeled 
for the detection of antibodies against the A. phagocytophilum P44 antigen and the B. 
burgdorferi C6 antigen, respectively, in dogs. According to the manufacturer, the test 
methodology is not species-specific and the test performs well in equine samples (28).  
Interpretation of serologic test results in non-endemic areas is challenging. False positive 
result may occur due to cross-reactivity of antibodies to similar organisms (30,96). Sensitivity 
for detection of antibodies varies between the different serologic tests and may be time-
dependent. That means that the expression of different immunogens of the pathogen and, 
hence, antibody production, varies according to the different stages of infection, as in the case 
of B. burgdorferi (27,48,53,97–99). Another challenge when interpreting serologic tests is the 
differentiation between active infection and exposure as discussed earlier.  
Although the vector I. scapularis is endemic in some areas of Canada, the prevalence of 
exposure to EGA and LB among horses (as detected by the presence of measurable antibody 
titers) is unknown. In endemic areas in the midwestern and northeastern US, seropositive 
horses are common and the majority of  seropositive horses are asymptomatic (18,25,45,58–
60,100). Increased evidence of tick-borne morbidity in horses appears to be related to the 
emergence of the tick vector in Canada (75). The frequency of exposure of horses in Canada 
to tick-borne organisms is poorly characterized and requires further investigation. One benefit 
of estimating seroprevalence in horses is that it provides a baseline for monitoring the 
behaviour of these tick-borne diseases in horses. As discussed, the anticipated increase in the 
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rate of exposure requires tight monitoring and application of control measures when 
indicated. 
For this study, it was hypothesized that based on a point-of-care ELISA, the 
seroprevalence of EGA and equine LB in SK, MB and ON is currently low. We estimated 
seroprevalences by testing convenience serum samples submitted to provincial diagnostic 
laboratories. Seroprevalence in this study was defined as the proportion of samples that tested 
positive for the presence of antibodies against A. phagocytophilum (seroprevalence of EGA) 
or B. burgdorferi (seroprevalence of LB). 
It was also hypothesized that the assessment of a sample as seropositive or seronegative 
does not differ between a point-of-care ELISA and laboratory-based serologic tests. 
Agreement between serologic was assessed by comparison of the proportion of positive tests 
and by use of an inter-rater agreement (Kappa) statistic.  
2.3 Materials and Methods 
2.3.1 Serum samples  
Equine serum samples were obtained from submissions to diagnostic laboratories in MB 
(Manitoba Agriculture, Food and Rural Initiatives Veterinary Diagnostic Services, Winnipeg), 
SK (Prairie Diagnostic Services, Saskatoon) and ON (Animal Health Laboratory, Guelph). To 
estimate seroprevalence in each province with 95% confidence, a required sample size of 100 
samples per province was calculated based on an estimate of at least 100,000 horses in each 
of the 3 provinces and an estimated seroprevalence of 2% for each disease in horses in 
Canada.  
The laboratories were asked to collect serum samples that were submitted between 
October and December 2011 and that contained at least 1ml serum. The collection period was 
chosen to maximize chances for positive serologic results. Horses are more likely to be 
infested with the adult stage of I. scapularis, which is active in the fall months, starting in 
September (13). Samples were categorized according to the month of submission and the 
province from which they originated. Taking time for seroconversion into account, we tested 
all the samples submitted in November first. If the number of samples submitted in November 
from an individual province did not reach 100, we then tested samples submitted in 
December. Samples submitted in October were only tested if those submitted in November 
and December did not add up to 100.  
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Samples were kept frozen at -20°C between collection and analysis in the investigator’s 
laboratory. The serum samples were supplied in accordance with the laboratory’s 
confidentiality rules and the study was approved by the Animal Research Ethics Board, 
University Committee on Animal Care and Supply (UCACS), at the University of 
Saskatchewan (protocol # 20120015).    
2.3.2 SNAP® 4Dx® ELISA testing 
Before testing, serum samples were thawed at room temperature and then centrifuged 
(Eppendorf 5702 centrifuge, Eppendorf, Mississauga, ON) for 10 minutes at 4400 rpm. The 
samples were tested for the presence of antibodies against B. burgdorferi and A. 
phagocytophilum using the SNAP® 4D ® ELISA according to manufacturer’s instructions.  
Briefly, 3 drops of serum and 4 drops of conjugate were mixed thoroughly in a sample 
tube. The entire content of the sample tube was added to the sample well. The sample was 
allowed to flow across the results window for 30-60 seconds. When the first color change 
appeared in the activation circle, the activator was pushed firmly until it was flush with the 
device body. The test result was read at 8 minutes. Any change in colour in the sample spots 
in the activation window was interpreted as a positive result, i.e. the presence of specific 
antibodies. Samples were re-frozen immediately following testing. 
2.3.3 Laboratory-based serologic tests  
Samples were re-tested at the Connecticut Veterinary Medical Diagnostic Laboratory 
(CVMDL). The frozen samples were shipped to the laboratory on ice overnight. All samples 
testing seropositive for EGA by SNAP® 4Dx® ELISA and 92 randomly selected 
seronegative samples were re-tested using an A. phagocytophilum IFA. All samples testing 
seropositive for LB by SNAP® 4Dx® ELISA and 92 randomly selected seronegative samples 
were re-tested using a whole cell B. burgdorferi ELISA confirmed by WB. The laboratory’s 
guidelines for interpretation of test results are summarized in Table 2.1. Samples were 
considered seropositive for EGA when the IFA titer was ≥80. Samples were considered 
seropositive for LB when a positive B. burgdorferi ELISA titer (≥1:160) was confirmed by a 
positive WB. Samples with equivocal or negative WB results were considered seronegative 
regardless of the ELISA titer. Samples with an ELISA titer <1:160 were considered 
seronegative and were not re-tested by WB. 
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2.3.4 Statistical analysis  
To estimate seroprevalence, the number of seropositive samples for EGA and LB by 
SNAP® 4Dx® ELISA was recorded and the overall and individual provincial proportions of 
positive samples were calculated with their 95% CI. Each sample was considered as 
representing a different horse.  
The number of seropositive and seronegative samples was recorded for each serologic 
test used. The two-tailed McNemar's test (VassarStats software, Website for Statistical 
Computation; http://www.vassarstats.net/index.html) was used to compare the proportion of 
positive test results between paired tests and p<0.05 was considered significant. When the 
McNemar’s test indicated no significant difference between the proportion of positive results, 
an inter-rater agreement was calculated, using the Kappa statistic (©2013 GraphPad Software, 
Inc., San Diego, CA). The magnitude of Kappa was interpreted as follows: ≤ 0 poor, 0.01-0.2 
slight, 0.21-0.4 fair, 0.41-0.6 moderate, 0.61-0.8 substantial, 0.81-1 almost perfect agreement 
(101).  
2.4  Results  
2.4.1 Samples  
A total of 626 serum samples were received.  Three hundred and seventy-seven serum 
samples that originated from SK were submitted to Prairie Diagnostic Services. Two hundred 
and fifteen serum samples that originated from MB were submitted to Prairie Diagnostic 
Services and Manitoba Agriculture, Food and Rural Initiatives Veterinary Diagnostic 
Services. A total of thirty-four samples that originated from ON, all submitted in October, 
were submitted to the Animal Health Laboratory (Table 2.2). 
Three hundred and seventy-six serum samples were tested with the SNAP® 4Dx® 
ELISA. Due to the fact that a low number of samples originated from ON, more than 100 
samples originating from SK and MB were tested (Table 2.2). All samples submitted from 
one province within one month, starting in November were tested. As only 34 samples were 
received from the MB lab, all of them were tested, including 6 from October (Table 2.2). In 
total, 202 samples originating from SK, 140 samples originating from MB and all 34 samples 
originating from ON were tested (Table 2.2).  
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2.4.2 Seroprevalence according to SNAP® 4Dx® ELISA testing 
Overall, 2 samples were seropositive for EGA and 6 samples were seropositive for LB 
(Table 2.3). No sample was seropositive for both EGA and LB. Based on the SNAP® 4Dx® 
ELISA results, the overall seroprevalence of EGA was 0.53% (95% CI: 0.09-2.12%) and the 
overall seroprevalence of LB was 1.6% (95% CI: 0.65-3.6%).  Table 2.3 shows the individual 
provincial seroprevalences.   
2.4.3 Agreement between the SNAP® 4Dx® ELISA and laboratory-based serologic tests  
Of the samples testing seropositive for EGA by SNAP® 4Dx® ELISA, one sample tested 
weakly positive (1:160) and the second sample tested strongly positive (1:10,240) by IFA. Of 
the samples testing seronegative for EGA by SNAP® 4Dx® ELISA, 67 samples tested 
negative (<1:80), 24 samples tested weakly positive (1:80-1:320) and one sample tested 
moderately positive (1:1280) by IFA (Table 2.4; also see Table 2.1 for test interpretation 
guidelines).  
Of the 6 samples that tested seropositive for LB by SNAP® 4Dx® ELISA, 3 were weak 
positive by WB and 3 were equivocal by WB and therefore categorized as seronegative for 
the purposes of agreement testing (Table 2.5; also see Table 2.1 for test interpretation 
guidelines). All of the SNAP® 4Dx® ELISA negative samples that tested positive by WB 
(n=11) were weakly positive by WB. One sample tested moderately positive by ELISA 
(1:1280) but was negative by WB. Repeated testing was done in the laboratory with identical 
result. This sample was interpreted to be seronegative for LB and the moderately high titer by 
whole cell ELISA was assumed to be due to cross-reactivity.  
According to the two-tailed McNemar’s test, the proportion of seropositive samples was 
significantly different between the SNAP® 4Dx® ELISA and laboratory-based IFA for EGA 
(p <0.000001), indicating a bias effect. The difference in the proportion of positive results 
was not significant (p = 0.057) between the SNAP® 4Dx® ELISA and ELISA/WB for LB. 
Agreement between the SNAP® 4Dx® ELISA and whole cell ELISA/WB for LB was fair, as 
indicated by a Kappa of 0.23 (95% CI: -0.03 - 0.50) (Table 2.6).  
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2.5 Discussion 
The objectives for this study were two-fold. The first goal was to estimate the 
seroprevalence of EGA and LB in horses in SK, MB and ON using a point-of-care (SNAP® 
4Dx®) ELISA.  This study reports the first seroprevalence estimate for EGA and LB of 
horses in Canada. Seroprevalence estimates for both EGA and LB fit well with the expected 
seroprevalence, suggesting that horses in Canada are currently at low risk for exposure to 
EGA and LB. 
Overall and provincial seroprevalences for EGA and LB were low which supports our first 
hypothesis (Table 2.3). In comparison to these results, the reported seroprevalence of EGA in 
the midwestern US is 3.8% in Ixodes non-endemic areas and up to 17.6% in Ixodes endemic 
areas (13). The reported seroprevalence of EGA in an Ixodes endemic area in California is 
10% (13). The reported seroprevalence of LB in horses in Ixodes endemic areas in the US is 
up to 60% (45,58–60).  
As established populations of Ixodes are known to occur in southeastern MB and in 
southern ON (39), one may expect an increased risk for exposure of horses in these provinces, 
with a higher seroprevalence of EGA and LB relative to an area where established 
populations of I. scapularis have not been detected such as SK. However, established 
populations of Ixodes in ON and MB are mostly isolated (39,75) and the level of exposure 
may differ between regions in each province. While we have no data about the distribution of 
the tested horses within the provinces, exposure of horses may also be explained by exposure 
to adventitious ticks introduced by migrating birds or local hosts. Indeed, the provincial and 
overall seroprevalence of EGA and LB found in our study was similar to the reported 
prevalence of A. phagocytophilum infection in I. scapularis ticks (1.4%) collected from 
migrating birds arriving in Canada (37). Since no established populations of I. scapularis 
have been detected in SK, it may be assumed that the most likely explanation for finding 
seropositive horses in this province would be exposure to adventitious ticks. However, the 
occurrence of unrecognized established populations of Ixodes in SK cannot be ruled out. 
Other possible explanations for seropositivity in horses from presumed non-endemic areas 
include travel of horses to endemic areas prior to sample collection, or collection of samples 
from horses that were imported from an endemic area. The same is also true for horses from 
endemic areas which may have been exposed outside their current area of residency. As no 
historical data, including travel history were available for the horses from which samples 
37 
 
originated, it is not certain whether the seropositive horses were all exposed to the diseases 
within Canada. Most of the serum samples used in this study were originally submitted for 
equine infectious anemia testing, which suggests that they originated from a specific 
population of horses that is likely to compete and, possibly, travel. It is therefore possible that 
some seropositive horses were exposed to EGA or LB outside of Canada. 
Due to the limited sample size, the difference in seroprevalence for EGA and LB among 
provinces was not assessed. It is worth mentioning that the seroprevalence estimate for ON 
needs to be interpreted with caution as it was based on a very small sample size which 
decreased the accuracy of the estimate. Another potential limitation of the seroprevalence 
estimates in the study is the source of the samples used. As there was no control over the 
origin of the samples, it is not certain that each sample represented an individual horse. 
However, as the majority of samples was originally submitted for equine infectious anemia 
testing, horses are typically tested once per season, and received samples were submitted in a 
time period of three months, it is most probable that the majority of samples represented 
different horses.  
The second aim was to assess the agreement between test results obtained by a point-of-
care ELISA and those obtained from standard laboratory-based serologic tests. When testing 
for antibodies against A. phagocytophilum, the lack of agreement between the tests was 
caused by the high proportion (27%) of seronegative samples by SNAP® 4Dx® ELISA that 
were seropositive by the A. phagocytophilum IFA (Table 2.4) as was indicated by a 
significant difference in the proportion of positive results between tests (McNemar’s test, 
Table 2.6). The differences between the test results may be attributable to differences in test 
methodology, such as the use of different immunogens. The SNAP® 4Dx® ELISA uses a 
peptide derived from the P44 protein, also known as the major surface protein 2 (MSP2), 
which is expressed on the cell membrane of A. phagocytophilum. In comparison, the A. 
phagocytophilum IFA uses whole A. phagocytophilum organisms in HL-60 cells fixed on 
slides (28). The whole A. phagocytophilum organisms may cross-react with antibodies against 
other, similar rickettsia (45), which may result in false positive results.  The fact that titers for 
the majority of IFA seropositive samples were weak positive may support non-specific 
reactivity, possibly due to cross-reactivity, implying false positive results in the IFA. 
Conversely, while being highly specific, the SNAP® 4Dx® ELISA may yield false negative 
results as it only detects antibodies against one major surface protein of A. phagocytophilum. 
It is also possible that exposed or previously diseased horses maintain positive antibody titers 
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that are detectable by IFA but not by SNAP® 4Dx® ELISA. Reportedly, antibodies against 
A. phagocytophilum in horses can be detected by IFA for up to 2 years (25). The mildly 
positive titers in the majority of IFA positive samples in our study may therefore suggest 
exposure without active infection, or resolving infection. 
When testing for antibodies against B. burgdorferi, the McNemar’s test indicated that the 
difference in the proportion of seropositive results between the SNAP® 4Dx® ELISA and 
ELISA/WB combination was not statistically significant. While the McNemar’s test assesses 
the difference in the proportion of positive results, Kappa assesses the agreement between 
both positive and negative results between the tests. Agreement testing indicated fair 
agreement according to a Kappa value of 0.23 (95% CI: -0.03 - 0.50). Variation in test results 
may be explained by differences in test methodology and the different immunogens used.  
The SNAP® 4Dx® ELISA uses a synthetic C6 peptide resembling the invariable region 
(IR6) of the membrane protein VlsE of B. burgdorferi. Anti-VlsE antibodies are expressed 
during natural B. burgdorferi infection (28).  B. burgdorferi VlsE is only expressed in the 
mammalian host, at 7 to 21 days post invasion by B. burgdorferi, and  anti-VlsE antibodies 
may be detected as early as 3-4 weeks following infection (40,41). It is therefore possible that 
some samples testing negative by SNAP® 4Dx® ELISA but positive by ELISA/WB were 
from horses in the early stages of infection, at which time the SNAP® 4Dx® ELISA might 
yield a false negative result. The whole cell ELISA/WB combination may detect antibodies 
produced during early infection, such as those produced against the outer surface protein C 
(Osp C). The Osp C is only expressed when the spirochete is transferred to a mammalian host 
(34,43) and an antibody response may be detected as early as 2-3 weeks after infection (54). 
An early antibody response may be supported by the fact that all the samples that were 
seronegative by SNAP® 4Dx® ELISA but seropositive by WB were weakly positive (Table 
2.1 and Table 2.5). However, it was previously suggested that spirochetes may not always 
express Osp C while in horses (45). Another study reported that antibodies to Osp C were 
detected in less than 25% of clinically diseased horses suggesting a short term duration of 
these antibodies in the circulation (54). Differences in antibody response between horses 
should be considered. 
A second explanation for the occurrence of SNAP® 4Dx® ELISA–negative but 
ELISA/WB-positive samples is the detection of exposed rather than actively infected horses 
with the latter test (41). This is supported by the laboratory guidelines for interpretation of 
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weak positive WB results that may indicate resolving infection (Table 2.1). While 
recommendations for WB use and interpretation in horses are not standardized, it is likely that 
the type of antigens expressed by B. burgdorferi is similar in different mammals (34,43). 
Previously reported B. burgdorferi antigens that are used for WB testing of equine samples 
include Osp A, Osp B, Osp C, Osp F, VlsE, flagellin and others (45,54), which are similar to 
antigens that are used for testing of human samples according to Centers for Disease Control 
and Prevention (CDC) recommendations (51). Unfortunately, we are not certain about the 
specific antigens that were used to define WB results as positive or negative in the diagnostic 
laboratory used for this study. While WB may not differentiate between active infection, 
previous exposure or resolving infection according to the commonly used antigens, the point-
of-care ELISA only detects anti-C6 antibodies compatible with active infection (28,46,52).  
Another potential explanation for SNAP® 4Dx® ELISA-negative but ELISA/WB 
positive samples is vaccination. The Outer surface protein A (Osp A) of B. burgdorferi is 
expressed in culture and in the unfed tick gut and mediates attachment of the spirochete to the 
tick gut (43). During movement of the spirochete to the salivary gland of the tick during a 
blood meal, the spirochete down-regulates expression of Osp A and up-regulates expression 
of Osp C. Currently available canine vaccines against Lyme borreliosis contain Osp A and 
some contain Osp C of B. burgdorferi (48). Although there are no commercially available 
Lyme vaccines labeled for horses (44), extra-label vaccination of horses with the canine Lyme 
vaccine is reported anecdotally.  In vaccinated animals that develop adequate levels of anti-
Osp A or anti-Osp C antibodies, the organism is typically controlled effectively upon 
exposure and expression of VlsE may not occur. Hence, vaccinated animals, and vaccinated 
animals exposed to B. burgdorferi are less likely to react on the SNAP® 4Dx® ELISA (28) as 
it tests for antibodies against C6 which resembles VlsE. Conversely, reactivity to Osp A and 
Osp C may be detected by WB in these animals. While reactivity to Osp A in the WB is 
commonly regarded as indicating vaccination (48,86), OspC reactivity in the WB is mostly 
interpreted as a marker for early infection (54). Thus, it is possible that some of the WB-
positive samples originated from Lyme vaccinated horses. 
Finally, the occurrence of samples testing negative by SNAP® 4Dx® ELISA but positive 
by ELISA/WB may be explained by false positive results obtained with the latter test. While 
the whole cell B. burgdorferi ELISA/WB combination is considered to be highly sensitive, its 
specificity may be lower in non-endemic areas or when it is used as a screening test alone 
(45,51). This is due to possible non-specific reactivity with antibodies against spirochete 
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flagellin or other heat shock proteins (45). Cross-reactivity with antibodies produced against 
similar spirochetes may therefore occur and could result in false positive test results (45,51). 
According to  CDC recommendations, the two-tier approach is not recommended for  
screening but rather as a diagnostic tool for clinical patients, due to the potential false positive 
results especially in non-endemic areas (51). Although the CDC recommendations concern 
testing in human patients, the two-tier testing approach used in horses in this study is similar 
with regard to methodology and antigens used.  
Three of the six samples testing seropositive for LB by SNAP® 4Dx® ELISA were 
negative when re-tested with the ELISA/WB combination. All three samples showed 
equivocal reactivity on the B. burgdorferi WB, which is considered insufficient in specificity 
and quantity and requires a follow-up sample for confirming or ruling out active infection 
(Table 2.1). It is possible that these 3 samples were taken from horses in the early stages of 
infection when antibody levels were low but sufficient to lead to a positive result on the 
qualitative SNAP® 4Dx® ELISA. Re-testing of the horses at a later time would have 
provided valuable information; however, this was not possible in the context of this study. On 
the other hand, these results may represent false positive results by SNAP® 4Dx® ELISA, 
which have previously been reported (54) when the test was compared to both an ELISA/WB 
combination and a Lyme multiplex assay defined as the gold standard by the authors.  
When using serologic testing in populations with a low seroprevalence, as we suspect is 
the case with Ixodes-borne diseases of horses in Canada, the positive predictive value of a test 
is expected to be low and the negative predictive value of a test is expected to be high (104). 
That means that while we can be more certain that negative results are true, we are less sure 
that positive results are true and this suggest that some false positive results may have been 
obtained in our study. Yet, the finding of seropositive horses for EGA and LB in this study 
and previously reported cases of EGA in Canada support the need to consider EGA and LB in 
veterinary practice in Canada. 
Although seroprevalence results according to the SNAP® 4Dx® ELISA were consistent 
with the expectation, supporting our first hypothesis, a lack of agreement between the 
SNAP® 4Dx® ELISA and laboratory based serologic tests for EGA and LB was found. 
Therefore, the second hypothesis was rejected. While the SNAP® 4Dx® ELISA reportedly 
differentiates active infection from exposure, the IFA and the ELISA/WB combination may 
not differentiate active infection from exposure (44,45,51) and may seem to be more adequate 
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for use in a seroprevalence studies. However, as discussed previously, these highly sensitive 
laboratory-based serologic tests may be more prone to false positive results in non-endemic 
areas (45,51).  
An important limitation in this study is the absence of validated gold standard serologic 
tests for EGA and LB in horses. Although these serologic tests are commonly used in horses 
no validation studies have been reported. The way samples were categorized as seropositive 
or seronegative for the purposes of agreement testing may represent another limitation of the 
study. For the WB, the equivocal and negative results were grouped together as seronegative 
and all positive levels of WB results were grouped together as seropositive. All positive IFA 
titers were grouped together as seropositive. A different cut-off for categorization as 
seropositive or seronegative could potentially have changed the assessment of agreement 
between the test results. It is further important to consider that assessment of samples as 
seropositive or seronegative in the absence of any clinical information does not allow drawing 
any conclusions with regard to the diagnostic usefulness of the evaluated tests. In a clinical 
setting, the interpretation of equivocal or weak positive test results benefits from additional 
clinical data and equivocal test results may be readily confirmed or ruled out through follow-
up testing or testing of convalescent samples. These were unavailable in the setting of this 
study. While test results may differ between available serologic tests, one should consider 
relevant clinical data as well as specific guidelines for the interpretation of titer magnitude 
when making a clinical diagnosis of EGA or LB.   
In summary, provincial and overall seroprevalence of EGA and LB according to the 
SNAP® 4Dx® ELISA was low. It is likely that a larger sample size from ON would have 
increased the accuracy of the seroprevalence estimate for that province. It was found that the 
assessment of a sample as a seropositive or seronegative for EGA and LB differed between 
the point-of-care ELISA and laboratory-based serologic tests. Further evaluation of the 
agreement between the SNAP® 4Dx® ELISA and available serological tests is thus 
warranted. Future studies should include an evaluation of the agreement between the SNAP® 
4Dx® ELISA and all available serologic tests.  
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2.6 Tables  
Anaplasma phagocytophilum IFA 
<1:80                       Negative 
1:80-1:320                Weak positive 
1:640-1:2,560           Moderately positive 
1:5,120-1:20,480               Strongly positive 
 
Borrelia burgdorferi ELISA 
≤1:80                       Negative 
1:160-1:640              Weak positive 
1:1,280-1:5,120         Moderate positive 
1:10,240-1:40,960     Strong positive 
 
Borrelia burgdorferi WB 
Negative                  No specific antibody reactivity 
Equivocal Some antibody reactivity, insufficient quantity and specificity 
(follow up sample in 3-4 weeks should show specific antibodies 
if infection is active) 
Weak             Positive reactivity to a small number of specific antigens, usually 
early infection but also resolving infection (recommend testing of 
a convalescent sample) 
Moderate          Shows multiple Bb specific antibody bands and some non-
specific bands, quantity and intensity less than “strong”, consider 
re-testing if treating                       
Strong Shows multiple Bb specific (as well as non-specific) antibody 
bands, usually accompanied by high ELISA titer, indicates 
chronic Bb infection (many months duration), consider re-testing 
if treating 
 
Table 2.1. Reference guidelines for interpretation of test results provided by the Connecticut 
Veterinary Medical Diagnostic Laboratory (CVMDL). IFA = Indirect immunofluorescence 
antibody assay, ELISA = Enzyme linked immunosorbent assay, WB = Western blot. 
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Laboratory Originated from 
SK 
Originated from 
MB 
Originated from 
ON 
PDS 175  (October) 
131 (November) 
71   (December) 
75  (October) 
57 (November) 
49 (December) 
 
MB Lab  6   (October) 
19 (November) 
9   (December) 
 
AHL   34  (October) 
Total submitted 377 215 34 
Total tested 202 140 34 
 
Table 2.2. Available serum samples and those actually tested, by province of origin, month of 
submission and diagnostic laboratory to which they were submitted. PDS= Prairie Diagnostic 
Services, Saskatoon SK. MB Lab= Agriculture, Food and Rural Initiatives Veterinary 
Diagnostic Services, Winnipeg, MB. AHL= Animal Health Laboratory, Guelph, ON. Bolded 
italic numbers represent numbers of samples that were tested. 
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SNAP® 4Dx® ELISA 
SK 
(n=202) 
MB  
(n=140) 
ON 
(n=34) 
Overall  
(n=376) 
EGA (positive) 1 1 0 2 
Seroprevalence 
(95% CI) 
0.49% 
(0.02-3.1) 
0.7% 
(0.03-4.5) 
0% 
(0-12.6) 
0.53% 
(0.09-2.1) 
LB (positive) 1 4 1 6 
Seroprevalence 
(95% CI) 
0.49% 
(0.02-3.1) 
2.9% 
(0.92-7.6) 
2.94% 
(0.15-17) 
1.6% 
(0.65-3.6) 
 
Table 2.3. Total number and proportion of samples seropositive for EGA and LB by SNAP® 
4Dx® ELISA. EGA= Equine granulocytic anaplasmosis, LB= Lyme borreliosis, SK = 
Saskatchewan, MB = Manitoba, ON = Ontario. 
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Sample  SNAP IFA 
1 
2 
3-13 
14-24 
25-26 
27 
+ 
+ 
- 
- 
- 
- 
1:160 
1:10,240 
1:80 
1:160 
1:320 
1:1280 
 
Table 2.4 Samples seropositive for EGA by one or two serologic tests. Titers are indicated as 
negative (-) or positive (+), positive titers are specified where applicable. SNAP= SNAP® 
4Dx® ELISA. IFA= Indirect immunofluorescence assay.  
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Sample SNAP ELISA / WB 
1 
2-3 
4-6 
7-12 
13-14 
+ 
+ 
- 
- 
- 
1280 / + 
2560 / + 
160 / + 
320  / + 
640 / + 
 
Table 2.5 Samples seropositive for LB by one or two serologic tests. Titers are indicated as 
negative (-) or positive (+), positive titers are specified where applicable. SNAP= SNAP® 
4Dx® ELISA. ELISA= Enzyme linked immunosorbent assay, WB= Western Blot.  
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 IFA for EGA ELISA   &  WB for LB 
+ - Total  + -  Total 
SNAP® 4Dx® ELISA + 2 0 2 + 3 3 6 
 - 25 67 92 - 11 81 92 
 Total  27 67 94 Total 14 84 98 
 
                                             p<0.000001 
 
 
p=0.057  
Kappa = 0.23 (-0.03 - 0.50) 
 
Table 2.6. Comparison between the SNAP® 4Dx® ELISA and IFA for EGA, and between 
the SNAP® 4Dx® ELISA and ELISA/WB combination for LB. For the comparison of the 
proportion of positive tests by McNemar’s test, p<0.05 was considered significant. The Kappa 
statistic (shown with 95% CI of the estimate) indicated fair agreement for LB. IFA = Indirect 
immunofluorescence assay, ELISA = Enzyme linked immunosorbent assay, WB = Western 
blot.  
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Transition to chapter 3 
In the previous study, equine serum samples were tested for antibodies against A. 
phagocytophilum and B. burgdorferi using a point-of-care ELISA and the results were 
compared to those of a laboratory-based A. phagocytophilum IFA and B. burgdorferi ELISA 
confirmed with WB, respectively.  Lack of agreement was found when a point-of-care ELISA 
was compared with IFA for EGA. Agreement was fair (Kappa 0.23) when the point-of-care 
ELISA and ELISA confirmed with WB were compared for LB.  It was found that testing with 
laboratory-based serologic tests yielded a significantly higher number of positive results than 
the SNAP® 4Dx® ELISA when testing for EGA but not for LB. In the next study, the goal 
was to compare results of testing equine serum samples by a point-of-care ELISA and 
additional serologic tests in more than one diagnostic laboratory to further understand the 
agreement between available serologic tests. The hypothesis was that the assessment of a 
sample as seropositive or seronegative for EGA or LB, respectively, is independent of the 
specific testing method used.  
The author of the thesis took part in obtaining funds for the second study and study 
planning in collaboration with Drs. K. Lohmann, T. Epp. H. Burgess, and managed sample 
collection, handling and testing the new set of equine serum samples. Subsequent to in-house 
testing, sample management and shipment of samples to the referral laboratories was done by 
the author. Recording and analysis of results was done by the author. This chapter will be 
submitted for publication in the Journal of Veterinary Diagnostic Investigation, which will 
hold copyright. 
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3. COMPARISON BETWEEN AVAILABLE SEROLOGIC TESTS FOR  
      DETECTING SEROPOSITIVITY FOR EQUINE GRANULOCYTIC  
      ANAPLASMOSIS AND LYME BORRELIOSIS IN HORSES IN CANADA 
3.1 Abstract 
To investigate agreement between available serologic tests for detection of seropositive 
samples for equine granulocytic anaplasmosis (EGA) and Lyme borreliosis (LB), 50 equine 
serum samples were tested using a point-of-care ELISA (SNAP® 4Dx® Plus ELISA, IDEXX 
Laboratories, Inc., Westbrook, ME) and laboratory-based serologic tests. Laboratory-based 
tests included two indirect immunofluorescence antibody assays (IFA) for antibodies against 
A. phagocytophilum and an IFA, an ELISA confirmed with Western Blot (WB), and an 
equine Lyme multiplex assay for antibodies against B. burgdorferi. Samples were assessed as 
seropositive or seronegative according to the manufacturer’s instructions for the SNAP® 
4Dx® Plus  it and each diagnostic laboratory’s guidelines. Results were compared between 
individual pairs of tests by comparing the proportion of positive results using the McNemar’s 
test and by using Kappa statistic for assessment of agreement. For detection of antibodies 
against A. phagocytophilum, the proportion of seropositive samples differed significantly 
between all 3 pairs of tests indicating lack of agreement between test pairs of serologic test for 
EGA. For detection of antibodies against B. burgdorferi, the proportion of seropositive 
samples was significantly different for 2 of the 6 pairs of tests indicating lack of agreement 
between these pairs.  For the other test comparisons, agreement ranged from poor to fair as 
was indicated by Kappa values.  It was concluded that assessment of samples as seropositive 
or seronegative for EGA and LB, respectively, differs between available serologic tests, likely 
due to differences in test methodology. Further investigation of the adequacy of available 
serologic tests for assessing disease exposure is warranted.    
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3.2  Introduction 
Equine granulocytic anaplasmosis (EGA) caused by Anaplasma phagocytophilum, and 
Lyme borreliosis (LB), caused by Borrelia burgdorferi, are important tick-borne diseases in 
horses. In North America, both organisms are transmitted by the same vector ticks Ixodes 
scapularis and Ixodes pacificus (13,16). Co-exposure to both organisms in horses was 
previously reported in the US (45). 
Ixodes species are endemic in the Northeast, Midwest and on the west coast of the US. 
Evidence for the presence of established populations of Ixodes in Canada is increasing in 
recent years (39,75,85) and Ixodes populations have been reported from Ontario (ON), 
Quebec (QC), Nova Scotia (NS), New Brunswick (NB), Manitoba (MB) and British 
Columbia (BC). It is anticipated that the geographic range of I. scapularis in Canada will 
expand in the upcoming decades and will extend further west and north (41,64,75,77,82). 
Cases of EGA in Canada have been reported in horses without history of recent travel, 
residing in areas with and without established populations of the vector (4–7). Lyme 
borreliosis has been reported in horses in Canada (8) but travel history for these horses was 
not reported. Concern over Ixodes- borne diseases in Canada is increasing and information 
about the seroprevalence of the diseases in horses in Canada was reported earlier in chapter 2.  
Clinical diagnosis of EGA or LB depends on the manifestation of typical clinical signs, 
geographic location and likelihood of exposure to the tick vector, and diagnostic testing. 
Detection of antibodies is important when studying the seroprevalence of these diseases and 
when defining the rate of exposure in a specific population or location. 
The indirect immunofluorescence antibody assay (IFA) is a commonly used serologic test 
for detection of antibodies against A. phagocytophilum (27) and is considered the gold 
standard of serologic testing for rickettsial diseases (24,27). Serum antibodies bind to A. 
phagocytophilum present in infected cells, e.g. HL-60 cells (27,105), on a slide and are then 
detected by addition of a fluorescein-labeled species-specific anti-antibody that binds the 
serum antibodies. Although IFA remains the principal diagnostic tool for the diagnosis of 
antibodies against A. phagocytophilum, there are no standardized antigens or conjugates, and 
there is no agreement on what constitutes a positive test result among the different 
laboratories that offer serologic testing (27). IFA tests may detect different antibodies at 
different stages of infection or time from exposure. Levels of antibodies are likely to increase 
with increased duration of infection (27). 
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The enzyme-linked immunosorbent assay (ELISA) and IFA are considered sensitive tests 
for detecting antibodies against B. burgdorferi in horses, with the ELISA reported to detect 
relatively more seropositive horses (43). To increase specificity, a two-tier approach has been 
adapted in horses. This method is similar to the recommended serodiagnostic approach to 
Lyme disease in humans (45,51). Initial screening with a sensitive technique, i.e. a whole cell 
ELISA or IFA, is followed, if positive, with a more specific Western Blot (WB) to detect 
antibodies against separated B. burgdorferi  antigens (43,51). The CDC recommends the  use 
of specific antigens to detect B. burgdorferi antibodies, which includes the use of at least 2 
out of 3 antigens for detection of IgM  and the use of at least 5 out of 10  antigens for 
detection of IgG (27,32,51). Due to the slow multiplication of the spirochete in the host, a 
detectable antibody response may take 3-8 weeks to develop, and the sensitivity of the 
ELISA/WB combined test may be low in the first few weeks of infection (48).  
The Equine Lyme multiplex assay (Animal Health Diagnostic Center, Cornell University, 
Ithaca, NY) uses antigen-labeled beads and detects antibodies against three B. burgdorferi 
antigens, namely the Outer surface proteins (Osp) A, C and F, in horse serum (48). B. 
burgdorferi Osp A is expressed while the spirochete is in the tick, Osp C is expressed during 
transmission to mammals and Osp F is expressed later during infection in the mammalian host 
(53). The use of these antigens allows detection of antibodies as early as 3 weeks post 
infection (53), which compares favorably to the IFA or ELISA with WB confirmation, where 
the earliest time of antibody detection averages 5 to 6 weeks after experimental infection in 
ponies (56). The Lyme multiplex assay also allows an assessment of the stage of infection, 
vaccination status and treatment success in horses if testing is repeated over time 
(48,53,55,106). In addition, the multiplex assay showed good agreement with C6 ELISA tests, 
including the SNAP® 4Dx® ELISA (IDEXX Laboratories, Inc., Westbrook, ME) in dogs and 
horses, using samples from both infected and non-infected animals (48,53). 
The point-of-care SNAP® 4Dx® ELISA uses a peptide derived from the 
immunodominant P44 protein of A. phagocytophilum for detection of antibodies against A. 
phagocytophilum. For detection of antibodies against B. burgdorferi, synthetic C6 peptide 
resembling the invariable region (IR6) of the B. burgdorferi membrane protein VlsE is used. 
Antibodies against VlsE are only produced during natural B. burgdorferi infection and testing 
can therefore distinguish natural infection from the antibody response to vaccination. The 
latter results in production of anti-Osp A but not anti-C6 antibodies  (52). According to the 
manufacturer (28), the SNAP® 4Dx® ELISA is not species-specific although it is currently 
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only licensed for use in dogs. In a study evaluating the test’s performance using 164 equine 
serum samples from endemic and non-endemic areas of the US  (28), both sensitivity and 
specificity of the SNAP® 4Dx® ELISA relative to a commercially available A. 
phagocytophilum IFA were 100%. The relative sensitivity and specificity of the SNAP® 
4Dx® ELISA compared to a B. burgdorferi Western Blot were 100% and 95%, respectively 
(26).  In horses experimentally infected with B. burgdorferi, a sensitivity of 63% and 
specificity of 100% for the SNAP® 4Dx® ELISA were further reported (29). Recently, the 
SNAP® 4Dx® ELISA has been replaced by an extended version of the same test, namely the 
SNAP® 4Dx® Plus ELISA, which adds testing for antibodies against Ehrlichia ewingii and 
Anaplasma platys (107). According to the manufacturer (Ramaswamy Chandrashekar, 
personal communication), the test methodology for detection of antibodies against A. 
phagocytophilum and B. burgdorferi has not changed. 
The positive and the negative predictive value of serologic tests depend on the prevalence 
of the diseases which is important to consider when using serologic tests in areas with a low 
seroprevalence of the disease, as is the case for EGA and LB in horses in Canada (104). That 
means that while we can be more certain that negative results are true, we may be less sure 
that positive results are true.  
In 2011, a small seroprevalence study using equine serum samples from SK, MB and ON 
was conducted by the authors. Samples were tested for the presence of antibodies against A. 
phagocytophilum and B. burgdorferi. As part of that study, results obtained by testing with 
the SNAP® 4Dx® ELISA were compared to results obtained when testing the same samples 
at one commercial veterinary diagnostic laboratory. We found lack of agreement between the 
SNAP® 4Dx® ELISA, the A. phagocytophilum IFA and the B. burgdorferi ELISA confirmed 
with WB, respectively. It was therefore suspected that results of serologic tests for EGA and 
LB may differ depending on test methodology, especially when applying these tests in non-
endemic populations with a low expected seroprevalence.  
As concerns over an increased incidence of tick-borne diseases in Canada may result in 
more frequent testing, and clinicians wishing to identify seropositive (or seronegative) horses 
may conceivably submit samples for testing with any of the available serologic tests, it would 
be helpful for the equine veterinarian to understand whether the available tests are 
comparable. The aim of the study reported here was therefore to further investigate the 
agreement between available serologic tests when classifying serum samples as seropositive 
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or seronegative for EGA and LB. The hypothesis for this study was that the assessment of a 
sample as seropositive or seronegative for EGA or LB, respectively, is independent of the 
specific testing method used. The agreement was evaluated between a point-of-care ELISA 
and two laboratory-based IFAs for EGA, and between a point-of-care ELISA, IFA, Lyme 
multiplex assay and ELISA/WB combination for LB. Agreement between tests was evaluated 
by use of an inter-rater agreement statistic and a comparison of the proportion of positive 
tests, using convenience serum samples. 
3.3  Materials and methods 
3.3.1.   Study design 
Fifty anonymous equine serum samples that were originally submitted for equine 
infectious anemia testing in April 2013, were obtained from Prairie Diagnostic Services Inc., 
Saskatoon, Saskatchewan. Only samples that contained at least 3.5 ml of serum following 
separation from cells were collected. The samples were divided into 3 aliquots of 1ml each 
and 1 aliquot of 0.5 ml and frozen at -20 ºC until analysis. One aliquot (0.5 ml) of each serum 
sample was tested in the principal investigator’s laboratory for presence of antibodies against 
A. phagocytophilum and B. burgdorferi using the point-of-care SNAP® 4Dx® Plus ELISA 
(IDEXX Laboratories, Inc., Westbrook, ME). The remaining 3 aliquots of each sample (1 ml 
each) were tested at 3 commercial veterinary diagnostic laboratories for antibodies against A. 
phagocytophilum and B. burgdorferi as described below. Samples were sent to the diagnostic 
laboratories frozen and on ice packs, using overnight courier shipment. 
3.3.2.  SNAP® 4Dx® Plus ELISA testing 
Serum samples were thawed at room temperature and centrifuged (Eppendorf 5702 
centrifuge, Eppendorf, Mississauga, ON) at 4400 rpm for 10 minutes. Samples were tested 
according to manufacturer’s instructions. Briefly, 3 drops of serum and 4 drops of conjugate 
were mixed thoroughly in a sample tube. The entire content of the sample tube was added to 
the sample well. The sample was allowed to flow across the results window for 30-60 
seconds. When the first colour change appeared in the activation circle, the activator was 
pushed firmly until it was flush with the device body. The test result was read at 8 minutes. 
Any change in colour in the sample spots in the activation window was interpreted as a 
positive result, i.e. the presence of antibodies. Samples were re-frozen immediately following 
testing. 
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3.3.3.  Laboratory-based serologic testing 
Samples were tested by A. phagocytophilum IFA at two veterinary diagnostic 
laboratories:  the Michigan State University Diagnostic Center for Population & Animal 
Health, Lansing, MI (DCPAH, from here on referred to as IFALAB1) and the Connecticut 
Veterinary Medical Diagnostic Laboratory, Storrs, CT (CVMDL, from here on referred to as 
IFALAB2). The laboratories used commercial IFA kits manufactured by Fuller (IFALAB1) 
and VMRD (IFALAB2), respectively. Test results were interpreted as seropositive or 
seronegative according to each laboratory’s guidelines (Table 3.1). Titers ≥1:160 were 
considered positive for IFALAB1 and titers ≥ 1: 80 were considered positive for IFALAB2. 
Samples were tested with the equine Lyme multiplex assay at the Animal Health 
Diagnostic Center, Ithaca, NY (AHDL), B. burgdorferi IFA at the DCPAH and B. burgdorferi 
ELISA confirmed with WB at the CVMDL. Test results were interpreted as seropositive or 
seronegative according to each laboratory’s guidelines (Table 3.2). For the equine Lyme 
multiplex assay, samples with a positive anti- Osp C titer (>1000) or positive anti-Osp F titer 
(>1250), were considered seropositive. For the B. burgdorferi IFA, samples with a titer ≥ 1: 
160 were considered seropositive. For the B. burgdorferi ELISA confirmed with WB, only 
samples that tested positive by WB were considered seropositive. Negative and equivocal WB 
results were considered negative, regardless of the ELISA titer. Samples that had an ELISA 
titer <1:160 were considered seronegative and were not re-tested by WB.  
3.3.4. Statistical analysis  
The number of seropositive and seronegative samples was recorded for each test used. 
The proportion of positive test results was compared between pairs of tests using a two-tailed 
McNemar's test (VassarStats software, Website for Statistical Computation; 
http://www.vassarstats.net/index.html) and p<0.05 was considered significant. When the 
McNemar’s test indicated no significant difference between the proportions of positive result, 
an inter-rater agreement was calculated for each pair-wise comparison of test results, using 
the Kappa statistic (©2013 GraphPad Software, Inc., San Diego, CA). The magnitude of 
Kappa was interpreted as follows: Kappa ≤0 poor, 0.01-0.2 slight, 0.21-0.4 fair, 0.41-0.6 
moderate, 0.61-0.8 substantial, 0.81-1 almost perfect agreement (101).  
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3.4  Results 
3.4.1   Results of serologic testing for EGA 
All 50 samples were seronegative for EGA by SNAP® 4Dx® Plus ELISA. When tested 
at IFALAB1, 6 samples were seropositive (1:320) and 44 samples were seronegative. When 
tested at IFALAB2, there were 15 seropositive results (1:80-1:320) and 35 seronegative 
results. Only 4 samples were seropositive in both laboratories. Interestingly, serum titers for 
these 4 samples differed between the two laboratories. At IFALAB1, all positive titers were 
1:320, while at IFALAB2, 3 titers were 1:80 and one was 1:320 (Table 3.3).  
3.4.2.  Agreement between serologic tests for EGA  
A significant difference in the proportion of positive tests was found in each pair-wise 
comparison of tests (Table 3.4) indicating lack of agreement between the tests.  
3.4.3.  Results of serologic testing for LB 
Thirty-one samples were seronegative on all tests. Individual test results for those 
samples testing positive on one or more tests (n=19) are presented in Table 3.5. Fourteen 
samples were seropositive based on only one test, 4 were seropositive based on 2 tests and 
only one sample was seropositive based on 3 tests. None of the samples was seropositive 
based on all 4 tests.      
3.4.4.  Agreement between serologic tests for LB 
The two-tailed McNemar’s test revealed that the proportion of positive tests differed 
significantly when comparing the SNAP® 4Dx® Plus ELISA to the IFA or to the Lyme 
multiplex assay, indicating lack of agreement. For the other pair-wise test comparisons, 
Kappa values indicated agreement that ranged from poor to fair (Table 3.6).  
When considering a positive result in any of the tests as evidence of seropositivity, 7 
samples were seropositive for both EGA and LB.  
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3.5  Discussion  
The investigation of the agreement between serologic tests for antibodies against A. 
phagocytophilum and B. burgdorferi in horse serum included comparisons between the point-
of-care SNAP® 4Dx® Plus ELISA and serologic tests available at 3 veterinary diagnostic 
laboratories. Tests were compared using two methods: Kappa to investigate inter-rater 
agreement and the McNemar’s test to compare the proportion of positive test results.  
For the serologic tests for EGA, the McNemar’s test indicated a significant difference 
between the proportions of positive results for each pair-wise comparison, suggesting lack of 
agreement between test results. This likely resulted from differences in test methodology. 
While the SNAP® 4Dx® Plus ELISA detects antibodies against a single antigen, namely P44 
(Msp2), both IFAs use whole cell A. phagocytophilum in infected cells. The whole A. 
phagocytophilum organisms may cross-react with antibodies against other, similar rickettsia 
(45), which may result in false positive results. All positive titers at IFALAB1 were 1:320. 
Interestingly, the instructions for the Fuller A. phagocytophilum IFA kit (used in Lab 1) 
specify that titers of 1:160-1:320 suggest either early infection, past exposure or may reflect 
cross-reactivity. Cross-reactivity may occur with antibodies that were produced against 
similar organism such as other Anaplasma species (45). As it is expected that each laboratory 
will validate a commercial test, standardize it and develop its own guidelines for test 
interpretation, guidelines provided by the diagnostic laboratory rather than those provided by 
the manufacturer of the test kit were used for test interpretation in this study. 
Another potential explanation for the difference in the proportion of positive results is 
that the SNAP® 4Dx® ELISA, while being highly specific, may yield false negative results 
as it only detects antibodies against one major surface protein of A. phagocytophilum. It is 
also possible that exposed or previously diseased horses maintain positive antibody titers that 
are detectable by IFA but not by SNAP® 4Dx® ELISA. Reportedly, antibodies against A. 
phagocytophilum in horses can be detected by IFA for up to 2 years (23).  
The lack of agreement between the 2 commercial IFA tests was somewhat surprising as it 
was expected that the tests would perform similarly. While the principal methodology is 
similar, IFALAB1 and IFALAB2 represented different commercially available IFA kits. 
Possible explanations are the use of different strains and conjugates and use of different 
calibration and reading systems in the individual labs, although, presumably, each lab sets up 
and validates its test based on known positive and negative samples. It is worth noting that the 
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IFALAB1 only defined samples as negative, inconclusive or positive whereas IFALAB2 used 
different categories for positive titers. Both labs further based their interpretation as 
seropositive or seronegative on different cut-off titers, which may also differentiate between 
the tests.  
As test methodology may impact on the occurrence of false positive and false negative 
results both have to be considered given the results obtained. The positive predictive value of 
diagnostic tests in low-prevalence populations, such as the one tested here is expected to be 
low and, thus, it is more probable that the IFA resulted in a considerable number of false 
positive results.  
The cut-off IFA titer values that were used to categorize samples as seropositive or 
seronegative for the purposes of agreement testing may represent a limitation of the study. A 
different cut-off may have changed the categorization of samples and could potentially have 
resulted in better agreement between the test results. However, when a cut-off titer of ≥ 1:160 
was used for both IFA tests, and also when a higher cut-off for defining seropositive samples 
(such as >1:320) was used, the agreement between tests was still poor at best, which supports 
the observed lack of agreement (data not shown).  
For the serologic tests for LB, the McNemar’s test indicated that the proportion of 
positive results was significantly different for only two of six pairs of tests, namely the 
SNAP® 4Dx® Plus ELISA and IFA, and the SNAP® 4Dx® Plus ELISA and Lyme multiplex 
assay. For the other pairs, the difference in the proportion of positive results was not 
statistically significant, while Kappa indicated lack of agreement. While the McNemar’s test 
assesses the difference between the proportion of positive results between the tests, Kappa 
assesses agreement between both positive and negative results. Although a low prevalence of 
seropositive results was expected in the population tested, adjustment of Kappa values was 
not deemed necessary or appropriate (101,108).  
When comparing the SNAP® 4Dx® Plus ELISA to a whole cell B. burgdorferi IFA, the 
significant difference in the proportion of  positive results was likely due to differences in test 
methodology. The SNAP® 4Dx® Plus ELISA uses synthetic C6 peptide resembling the 
invariable region (IR6) of the membrane protein VlsE of B. burgdorferi, whereas the whole 
cell IFA detects a variety of antibodies that are directed against different immunogens of B. 
burgdorferi and thus may yield a higher number of positive results. While the VlsE antigen is 
considered to be expressed only during active infection, the whole cell B. burgdorferi IFA 
59 
 
may also detect  antibodies due to exposure alone (44). While the IFA is highly sensitive 
(43,45,51), false positive results may occur due to non-specific reactivity with antibodies 
against flagellin or heat shock proteins of similar organisms (45), such as other Borrelia 
species or other similar spirochetes. While 2 other Borrelia species, namely B. miyamotoi and 
B. kurtenbachii have been previously reported to infect I. scapularis ticks in Canada (41), 
their clinical significance is not clear. Further investigation of Borrelia variants is therefore 
warranted and may enable better interpretation of serologic tests.  
Anti-VlsE antibodies may not be detected until 3-4 weeks following infection (40,41) and 
it is therefore possible that some samples testing negative by SNAP® 4Dx® ELISA were 
from horses in the early stages of infection, at which time the SNAP® 4Dx® ELISA would 
yield a false negative result. These samples may have been detected by IFA as the latter is 
expected to detect early antibodies such as those produced against the outer surface protein C 
(Osp C)(43,45). Osp C is only expressed when the spirochete is transferred to a mammalian 
host (34,43) and an antibody response may be detected as early as 2-3 weeks after infection 
(54). However, it was previously suggested the spirochete may not always express Osp C 
while in horses (45). Another study reported that antibodies to Osp C were detected in less 
than 25% of clinically diseased horses suggesting a short term duration of these antibodies in 
the circulation (54). Differences in the antibody response between horses should therefore be 
considered.   
When comparing the SNAP® 4Dx® Plus ELISA and the Lyme multiplex assay, the 
McNemar’s test indicated a significant difference in the proportion of positive results. Again, 
differences in test methodology were most likely the cause for the variation in test results. 
While the SNAP® 4Dx® Plus ELISA detects anti-C6 antibodies indicating active infection, 
the Lyme multiplex assay detects antibodies against 3 surface antigens of B. burgdorferi, 
namely the Osps A, C and F, which are expressed in different stages of infection (48). 
Detection of these different outer surface proteins reportedly allows the differentiation of 
early infection, chronic infection and an immune response to vaccination (48). Interestingly, 
the only sample that was positive by SNAP® 4Dx® Plus ELISA yielded an equivocal result 
in the Lyme multiplex assay (Osp F). According to the laboratory guidelines, a single 
equivocal Osp F value suggests a non-specific reaction. This result was surprising given that a 
previous study in horses described a strong correlation between the detection of antibodies 
against C6 in the SNAP® 4Dx® ELISA and detection of antibodies against Osp F in the 
Lyme multiplex assay (54). One possible explanation is a false positive result in the SNAP® 
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4Dx® Plus ELISA; however, as this sample was the only sample that was positive in 3 of 4 
tests, the possibility of a false negative result in the Lyme multiplex assay may seem more 
likely.  
The four samples that had  a positive Osp C titer in the Lyme multiplex assay and were 
negative in all other tests (Table 3.4) may indicate a very early antibody response (54) which 
was not detected by the other tests. It has also been suggested that the antibody response to 
Osp F starts earlier than the response to C6 (54) in horses, which may explain why all samples 
testing positive for anti-Osp F antibodies were negative by SNAP® 4Dx® Plus ELISA.  
The best agreement, which was still only fair (Kappa 0.31), was obtained when the 
SNAP® 4Dx® Plus ELISA was compared with the ELISA/WB combination. In contrast to 
this finding, a relative sensitivity of 100% and relative specificity of 95% for the SNAP® 
4Dx® ELISA compared to a B. burgdorferi WB in horses were previously reported (28). The 
previous study used samples that were initially submitted for Lyme testing and originated 
from potentially infected horses in endemic areas. Thus, the positive predictive value may 
have been higher than in the study reported here, where samples were collected anonymously 
and information about the horses was not available. The positive predictive value of serologic 
tests for Lyme borreliosis in non-endemic areas such as Canada is likely low.  
The variation in test results observed here may be explained by differences in test 
methodology and the different immunogens used. The SNAP® 4Dx® ELISA uses a synthetic 
C6 peptide to detect anti-VlsE antibodies as early as 3-4 weeks following infection (40,41). It 
is therefore possible that some samples testing negative by SNAP® 4Dx® ELISA but positive 
by ELISA/WB were from horses in the early stages of infection, at which time the SNAP® 
4Dx® ELISA might yield a false negative result. The whole cell ELISA/WB combination 
may detect antibodies produced during early infection, such as those produced against the 
outer surface protein C (Osp C) which may be detected as early as 2-3 weeks after infection 
(54). An early antibody response may be supported by the fact that all the samples that were 
seronegative by SNAP® 4Dx® ELISA but seropositive by WB were weakly positive (Table 
3.1).  
A second explanation for the occurrence of SNAP® 4Dx® ELISA–negative but 
ELISA/WB-positive samples is the detection of exposed rather than actively infected horses 
with the latter test (41). This is supported by the laboratory guidelines for interpretation of 
weak positive WB results that may indicate resolving infection. While recommendations for 
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WB use and interpretation in horses are not standardized, it is likely that the type of antigens 
expressed by B. burgdorferi is similar in different mammals (34,43). Previously reported B. 
burgdorferi antigens that are used for WB testing of equine samples include Osp A, Osp B, 
Osp C, Osp F, VlsE, flagellin and others (45,54), which are similar to antigens that are used 
for testing of human samples according to Centers for Disease Control and Prevention (CDC) 
recommendations (51). Unfortunately, we are not certain about the specific antigens that were 
used to define WB results as positive or negative in the diagnostic laboratory used for this 
study. While WB may not differentiate between active infection, previous exposure or 
resolving infection according to the commonly used antigens, the point-of-care ELISA only 
detects anti-C6 antibodies compatible with active infection (28,46,52).  
Another potential explanation for SNAP® 4Dx® ELISA-negative but ELISA/WB 
positive samples is vaccination. The Outer surface protein A (Osp A) of B. burgdorferi is 
expressed in culture and in the unfed tick gut and mediates attachment of the spirochete to the 
tick gut (43). Upon movement of the spirochete to the salivary gland of the tick during a 
blood meal, the spirochete down-regulates expression of Osp A and up-regulates expression 
of Osp C. Currently available canine vaccines against Lyme borreliosis contain Osp A and 
some contain Osp C of B. burgdorferi (48). Although there are no commercially available 
Lyme vaccines labeled for horses (44), extra-label vaccination of horses with the canine Lyme 
vaccine is reported anecdotally.  In vaccinated animals that develop adequate levels of anti-
Osp A or anti-Osp C antibodies, the organism is typically controlled effectively upon 
exposure and expression of VlsE may not occur. Hence, vaccinated animals are less likely to 
react on the SNAP® 4Dx® ELISA (28) as it tests for antibodies against C6 which resembles 
VlsE. Conversely, reactivity to Osp A and Osp C may be detected by WB in these animals. 
While reactivity to Osp A in the WB is commonly regarded as indicating vaccination (48,86), 
OspC reactivity in the WB is mostly interpreted as a marker for early infection (54). Thus, it 
is possible that some of the WB-positive samples originated from Lyme vaccinated horses. 
Finally, the occurrence of samples testing negative by SNAP® 4Dx® ELISA but positive 
by ELISA/WB may be explained by false positive results obtained with the latter test. While 
the whole cell B. burgdorferi ELISA/WB combination is considered to be highly sensitive, its 
specificity may be lower in non-endemic areas or when it is used as a screening test alone 
(45,51). This is due to possible non-specific reactivity with antibodies against spirochete 
flagellin or heat shock proteins (45). Cross-reactivity with antibodies produced against similar 
spirochetes may therefore occur and could result in false positive test results (45,51). 
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According to CDC recommendations, the two-tier approach is not recommended for  
screening but rather as a diagnostic tool for clinical patients, due to the potential for false 
positive results, especially in non-endemic areas (51). Although the CDC recommendations 
concern testing in human patients, the two-tier testing approach used in horses in this study is 
similar with regard to methodology and antigens used.  
It is worth mentioning that the majority of samples testing seropositive in the ELISA/WB 
combination, including the one that was also positive by the SNAP® 4Dx® Plus ELISA, 
were weakly positive by WB. Weakly positive WB results suggest early or resolving infection 
with recommendation for follow-up sampling in 3-4 weeks. Accepting only moderately 
positive WB as positive would have actually resulted in better agreement with the SNAP® 
4Dx® Plus ELISA (data not shown).  
Slight agreement (Kappa 0.02), was found when the IFA was compared to the Lyme 
multiplex assay. As discussed earlier, the Lyme multiplex assay detects antibodies against B. 
burgdorferi-specific Osp antigens (Osp A, C, F) that are expressed at different times after 
infection or after vaccination (48,54). In contrast, the whole cell IFA may also detect 
antibodies targeting less specific B. burgdorferi antigens (45,109) such as flagellin and heat 
shock proteins. Thus, it is not clear why 8 of the 10 samples that were positive by Lyme 
multiplex assay were negative by IFA. One possible and partial explanation is that in 4 of 
these samples, positive results in the Lyme multiplex assay were based on relatively low anti-
Osp C titers. Based on previous reports,  anti-Osp C antibodies in horses are only detected for 
a short period of time after infection (45,54), and it is therefore possible that very early or 
diminishing titers of anti-Osp C antibodies were not detected by the IFA.  
When comparing the ELISA/WB combination with the IFA, agreement was considered 
slight as well (Kappa 0.18). The two-tier approach for serologic testing for LB, as 
recommended by the CDC (51), uses the more specific WB to confirm positive or equivocal 
ELISA or IFA results and was designed  to improve specificity of diagnostic testing in human 
patients. The CDC recommends the use of specific bands to detect B. burgdorferi antibodies, 
which  includes the use of at least 2 out of 3 specific bands for detection of IgM presence and 
the use of at least 5 out of 10 specific bands for detection of IgG (27,32,51). As the WB is 
considered to be more specific than the IFA and the ELISA (43,45,51), the lower number of 
positive results and higher number of negative results compared with the IFA (Table 3.5) was 
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expected. As discussed earlier, false positive results in the IFA test may result from cross-
reactivity with antibodies against similar spirochetes.   
When comparing the Lyme multiplex assay to the ELISA confirmed with WB, the 
agreement was considered to be poor or the same as agreement by chance alone (Kappa 0). As 
discussed earlier, WB testing in horses typically includes assessment of reactivity to Osp 
antigens, some of which are also used in the Lyme multiplex assay. However, the WB is able 
to detect additional antibodies against other B. burgdorferi antigens while the Lyme multiplex 
assay only detects antibodies against 3 specific B. burgdorferi Osp antigens that are expressed 
at certain times after infection. Thus, it was surprising that a higher number of seropositive 
samples were obtained by the Lyme multiplex assay. Interestingly, 4 of the 5 samples testing 
positive by ELISA/WB showed a weak response in the WB, which may indicate early or 
resolving infection. Only one sample that was weakly positive by WB was Osp F positive in 
the Lyme multiplex assay. A resolving infection was likely the case in this sample. Another 2 
samples that were weakly positive by WB had equivocal titers for Osp F, suggesting non-
specific reactivity. According to guidelines from both laboratories, follow-up sampling would 
have been recommended to conclude whether the infection was active or not. The only sample 
that was moderately positive by WB was negative for antibodies to any of the Osp antigens. 
When taking into account all 13 samples that were equivocal by WB (counted as negative), 
only 2 of them were positive according to Osp C and Osp F reactivity on the Lyme multiplex 
assay. Thus, even the use of a less conservative cut-off for the categorization of seropositive 
samples in our agreement analysis would likely not have changed our results (data not 
shown). In contrast to our study, better agreement between the Lyme multiplex assay and WB 
when testing horse serum from presumed infected horses has been reported (54). While, 
presumably, some of the antigens used are overlapping between the tests, one may assume 
that differences in test methodology, test validation and standardization exist between the 
tests, which may account for the differences in test results observed in the study reported here. 
As was discussed in the context of EGA testing earlier, assessing samples as seropositive 
or seronegative for LB based on serologic testing at one point in time is limited. While it is 
reasonable to assume that the categorization of samples as seropositive or seronegative may 
have affected the agreement analysis, all equivocal test results were categorized according to 
what was considered most likely to reflect the presence or absence of specific antibodies. 
Considering low prevalence and laboratory recommendations for interpretation of equivocal 
results all equivocal results were categorized as negative.   
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Another limitation of the study is the absence of validated gold standard serologic test for 
EGA and LB in horses. While these tests are commonly used, validation studies in horses are 
lacking. It is also important to consider that assessment of samples as seropositive or 
seronegative was done in the absence of any clinical information and that, therefore, it is not 
possible to draw any conclusions with regard to the diagnostic usefulness of the evaluated 
tests. For example, in a clinical setting, interpretation of weak positive results benefits from 
additional clinical data and infection may be readily confirmed or ruled out with follow-up 
testing or testing of convalescent samples. These were unavailable in the setting of this study. 
Previously reported sensitivity and specificity of available serologic tests (25,28,45,46,54) 
was high when known positive and known negative samples were tested. When using 
serologic tests in the context of making a clinical diagnosis of EGA or LB, one should 
consider relevant clinical data as well as specific guidelines for interpretation of titer 
magnitude.  
In summary, agreement between serologic tests varied from poor to fair, thus our 
hypothesis was rejected.  The observed differences may be attributable to the different test 
methodologies and, specifically, the different antigens that were used. Differences in the 
categorization of test results as positive or negative may also play a role, such as in the case of 
IFA tests for EGA. Overall, the laboratory-based serologic tests assessed a higher number of 
samples as seropositive for EGA and LB compared to the point-of-care ELISA. With regard 
to LB, one likely explanation for this observation is that the point-of-care ELISA is limited to 
detecting active infection, while laboratory-based serologic tests may have limited ability to 
differentiate active infection from exposure. Another potential explanation for the difference 
between serologic tests for both EGA and LB is a difference in susceptibility to cross-
reactivity, which is suggested to happen particularly in whole cell tests. As low 
seroprevalence in the population of horses from which samples were derived was assumed, it 
is necessary to consider that these findings are to some extent due to false positive results. 
Given the observed differences in test results and the difficulties in test interpretation in the 
absence of clinical signs of disease, general screening of the horse population for tick-borne 
diseases in non-endemic areas may not be warranted until further information about the 
adequacy of available serologic tests for assessing exposure versus active infection is 
available. 
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3.6. Tables 
Testing for antibodies against A. phagocytophilum 
 
IFALAB1  
< 1:80                         Negative 
1:80                            Inconclusive (recommend re-testing of a convalescent  sample in 
                                   3-4 weeks) 
≥1:160                        Positive                               
 
IFALAB2 
<1:80                          Negative 
1:80-1:320                  Weak positive 
1:640-1:2560              Moderate positive 
1:5,120-1:20,480        Strong positive 
 
 
Table 3.1. Reference guidelines for interpretation of test results provided by the referral 
diagnostic laboratories.  IFA = Indirect immunofluorescence assay.  
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Testing for antibodies against B. burgdorferi 
 
  B. burgdorferi ELISA  
   ≤1:80                                   Negative 
  1:160-1:640                          Weak  positive 
  1:1280-1:5120                      Moderate positive 
  1:10,240-1:40,960                Strong positive 
 
  B. burgdorferi WB  
  Negative:                              No specific antibody reactivity. 
  Equivocal:                            Some antibody reactivity, insufficient quantity and specificity 
                                             (follow up sample in 3-4 weeks should show specific antibodies if infection is active). 
  Weak:                                   Positive reactivity to a small number of specific antigens, usually early infection but also resolving  
                                                infection (recommend testing of a convalescent sample). 
  Moderate:                             Shows multiple Bb specific antibody bands and some non-specific bands, quantity and intensity less  
                                                than the “strong”, consider re-testing if treating.                    
 Strong:                                   Shows multiple B. burgdorferi specific (as well as non-specific) antibody bands, usually accompanied  
                                                by high ELISA titer, indicates chronic B. burgdorferi infection (many months duration). 
   
B. burgdorferi IFA  
  <1:160                                  Negative 
  1:160-1:640                          Weak-moderate /equivocal 
>1:1280                               Fairly high (recent infection) 
 
 
 
6
6
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Testing for antibodies against B. burgdorferi (cont.) 
 
Lyme Multiplex Assay 
  Negative:                             Negative values for the antibodies to all 3 Osp antigens are predictive that the horse is not infected. If  
                                               only one or two values are in the negative range, see interpretation for equivocal or positive values for  
                                               the corresponding Osp antigen. 
  Equivocal:                            Equivocal values can indicate very early infection or nonspecific serum reaction. If no positive Osp  
                                               results the horses need to be retested in 2-3 weeks. If 1 or 2 values are in the positive range see  
                                               interpretation for positive Osp. 
  OspA (>2000-28,000)         Positive values typically observed in vaccinated animals, may rise during infection. If antibodiesto  
                                               OspC and or OspF are positive along OspA horses should be considered as infected with B. burgdorferi. 
  OspC (>1000-10,000)         Positive values to OspC only indicate early infection. Antibodies to OspA can be also elevated during early  
                                               infection.  
  OspF (>1250-26,000)         Positive value to OspF only are predictive for chronic infection stages. Positive values for  OspC and OspF  
                                               in the same sample are indicators for an infection that occurred several weeks ago and is moving towards  
                                               chronic infection stage. 
 
Table 3.2. Reference guidelines for interpretation of test results provided by the referral diagnostic laboratories. IFA = Indirect 
immunofluorescence assay, ELISA = Enzyme linked immunosorbent assay, WB = Western blot, Osp = Outer surface protein.
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Sample SNAP IFALAB1 IFALAB2 
1-8 - - 1:80 
9 - - 1:160 
10-11 - - 1:320 
12-13 - 1:320 - 
14-16 - 1:320 1:80 
17 - 1:320 1:320 
 
Table 3.3. Samples seropositive for EGA by one or two serologic tests. Titers are indicated as 
negative (-) or positive (+), positive titers are specified where applicable. SNAP= SNAP® 
4Dx® Plus ELISA. IFALAB1= Indirect immunofluorescence assay in laboratory 1 
(DCPAH). IFALAB2 = Indirect immunofluorescence assay in laboratory 2 (CVMDL). 
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IFALAB1 
+ 
 
- 
 
Total 
SNAP    + 0 0 0 
               - 6 44 50 
             Total 6 44 50 
p=0.031 
 
 
IFALAB2 
+ 
 
- 
 
Total 
SNAP    + 0 0 0 
               - 15 35 50 
              Total 15 35 50 
p=0.000061 
 
 
IFALAB2 
+ 
 
- 
 
Total 
IFALAB1  + 4 2 6 
                    - 11 33 44 
                   Total 15 35 50 
p=0.022 
 
 
Table 3.4. Comparison between pairs of serologic tests for EGA. SNAP= SNAP® 4Dx® Plus 
ELISA. IFALAB1= A. phagocytophilum IFA in laboratory 1.  IFALAB2= A. 
phagocytophilum IFA in laboratory 2. Differences between the proportions of positive results 
were significant for all pairs (p<0.05 on the McNemar’s test) indicating lack of agreement 
between test results.  
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Sample SNAP IFA 
Lyme Multiplex Assay 
OspA             OspC                  OspF 
ELISA/WB 
1 + 640 - - - 1280 / + 
2 - 160 - 10,573 - - / NA 
3 - 640 - 1604 - - /NA 
4 - 160 - - - 2560 / + 
5 - - - - 4134 320/ + 
6 - 2560 - - - 640 / - 
7 - 320 - - - 320 / - 
8 - 320 - - - 320 / - 
9 - 640 - - - 320 / - 
10 - 640 - - - 640 / - 
11 - - 2017 1144 - 160 / - 
12 - - - 1091 - -  / NA 
13 - - - 1030 - - / NA 
14 - - - 1079 - - / NA 
15 - - - - 12,996 160 / - 
16 - - - - 4312 -/ NA 
17 - - - - 7357 -/ NA 
18 - - - - - 640/ + 
19 - - - - - 320/ + 
 
Table 3.5. Samples seropositive for LB by one or more serologic tests. Titers are indicated as 
negative (-) or positive (+), positive titers are specified where applicable. NA= Not applicable. 
SNAP= SNAP® 4Dx® Plus ELISA. IFA= Indirect immunofluorescence assay. OspA,C,F= 
Outer surface protein A, C, F. ELISA= Enzyme linked immunosorbent assay, WB= Western 
Blot. ELISA/WB = Only positive ELISA results that were confirmed by WB were considered 
as positive. Samples with negative ELISA results were not re-tested with WB. 
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IFA 
+ 
 
- 
 
 Total 
SNAP                  + 1 0  1 
                             - 8 41  49 
                            Total 9 41  50 
p=0.008  
 
 
Multiplex 
Assay 
+ 
 
 - 
 
Total 
SNAP                  + 0 1  1 
                             - 10 39  49 
                            Total 10 40  50 
p=0.012 
 
 
ELISA/WB 
+ 
 
- 
 
 Total 
SNAP                   + 1 0  1 
                              - 4 45  49 
                             Total 5 45  50 
p=0.125 
Kappa    0.31 (95% CI: 0.16 - 0.78) 
 
Multiplex 
Assay 
+ 
 
- 
 
 Total 
IFA                      + 2 7  9 
                              - 8 33  41 
                             Total 10 40  50 
p=1   
Kappa     0.02 (95% CI: -0.26 - 0.31)                                      
 
ELISA/WB 
+ 
 
- 
 
 Total 
IFA                       + 2 7  9 
                              - 3 38  41 
                             Total 5 45  50 
p=0.344 
Kappa    0.18 (95% CI: 0.15 - 0.51) 
 
ELISA/WB 
+ 
 
- 
 
 Total 
Multiplex Assay  + 1 9  10 
                              - 4 36  40 
                             Total 5 45  50 
p=0.267  
Kappa     0 (95% CI: 0.26 - 0.26) 
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Table 3.6. Comparison between pairs of serologic tests LB. For the comparison of the 
proportion of positive tests by McNemar’s test, p<0.05 was considered significant. Kappa 
values indicated agreement that ranged from poor (0) to slight (0.02 and 0.18) and fair (0.31) 
between individual pairs of serologic tests. SNAP= SNAP® 4Dx® Plus ELISA. IFA= 
Indirect immunofluorescence assay. ELISA= Enzyme linked immunosorbent assay, WB= 
Western Blot.  
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Transition to chapter 4 
 The previous studies composing this thesis revealed that samples from horses in Canada 
may be seropositive for EGA and LB. Based on the first study, seroprevalence of EGA and 
LB in SK, MB and ON was low. As the samples for the first two studies were provided 
without identifying information, no information about the tested horses was available. For 
example, it was not possible to confirm whether seropositive samples originated from horses 
that were exposed within their province of residence or whether horses may have been 
exposed during travel within or outside of Canada.  Thus, it was of interest to compare 
management factors such as pasture access, travel history, history of infestation with ticks, 
and signalment between horses testing seropositive or seronegative for EGA and LB, 
respectively, in the previous studies. It was hypothesized that management factors would not 
differ between seropositive and seronegative horses. Mail-out surveys were used to collect 
this information and anonymity of the horses and horse owners was maintained through 
collaboration with the diagnostic laboratories that originally supplied the samples.  
 Survey planning, design and editing of surveys, survey distribution, recording and 
description of results was done by the author of this thesis in collaboration with the research 
team (Drs. Lohmann, Epp, Burgess). As no statistical analysis was done in this study it will 
not be submitted for publication in the format presented here. Instead, a portion of the 
descriptive data (2011 surveys) will be used as an addition to chapter 2 that will be submitted 
for publication in the Canadian Veterinary Journal. 
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4 COMPARISON OF MANAGEMENT FACTORS BETWEEN HORSES TESTING 
POSITIVE OR NEGATIVE FOR ANTIBODIES AGAINST ANAPLASMA 
PHAGOCYTOPHILUM AND BORRELIA BURGDORFERI IN CANADA 
4.1 Abstract 
 Equine granulocytic anaplasmosis (EGA) and Lyme borreliosis (LB) are tick-borne 
diseases transmitted by the vector ticks I. scapularis and I. pacificus. Established populations 
of the ticks have been reported from a few provinces in Canada. Clinical cases of EGA and 
LB have been reported in horses in Canada. In previous studies (see chapters 2 and 3), 
serologic evidence of exposure to both EGA and LB in horses in Canada was reported. The 
aim of this study was to identify potential risk factors for exposure in these same horses. The 
hypothesis was that management factors would not differ between seropositive and 
seronegative horses. A total of 392 anonymous surveys were sent to the owners of horses 
tested in previous studies, via the laboratories that supplied the samples. Surveys included 
questions concerning signalment of the horse, province of residence, timing of pasture access, 
visible tick infestation, history of travel and Lyme vaccination, and history of previous 
diagnosis with a tick-borne disease. A low response rate of 11.5% (45 of 392 surveys 
returned) and a low number of seropositive compared to seronegative animals precluded 
statistical analysis. The median age of horses seropositive for EGA was higher than that of the 
seronegative horses. For both diseases, the majority of seropositive horses was pasture-housed 
in the fall and had not travelled for at least 12 months prior to sample collection. None of the 
owners of seropositive horses reported seeing ticks on their horses. Potential risk factors for 
exposure to tick-borne diseases in Canada were identified in this study and should be explored 
in future investigations. 
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4.2 Introduction 
 Ixodes scapularis and I. pacificus are the common vectors for equine granulocytic 
anaplasmosis (EGA, caused by Anaplasma phagocytophilum) and Lyme borreliosis (LB, 
caused by Borrelia burgdorferi) in North America. In Canada, I. scapularis populations are 
currently established in a few locations in southern Ontario (ON) and Quebec (QC), Nova 
Scotia (NS), New Brunswick (NB), and in south east Manitoba (MB) (39,64). I. pacificus is 
established in a few locations in British Columbia (BC) (40,64,77,81,83,110).  
 Ixodes-borne diseases are an emerging concern in Canada (38,41,64). Granulocytic 
anaplasmosis has been reported in horses (4–6), dogs (89,93) and humans (94) in Canada, 
with EGA reported from areas with (4,5,7) and without (6) established populations of the 
vector. Reportedly, the affected horses did not travel outside their province of residence for at 
least a few years before diagnosis, which suggests that these horses were exposed to infected 
Ixodes within Canada. Horses living in non-endemic areas were probably exposed to infected 
adventitious ticks, for example ticks brought into the province on migrating birds. 
 Lyme borreliosis has been reported in horses, dogs and humans (8,38,39,89,90,111) in 
Canada. An increased risk for LB exposure has been reported in humans in eastern Canada, 
and in dogs in areas bordering the northeastern US (90).  
 While seroprevalence estimates for EGA and LB were previously reported for SK, MB 
and ON (see chapter 2), information about risk factors for exposure to these diseases in horses 
is lacking. The risk of tick infestation and infection with tick-borne organisms is likely 
increased with increased exposure to the vector such as in pastured horses (50), and it is thus 
possible that management factors such as travel or outdoor access during periods of vector 
activity contribute to the risk of encountering tick-borne infections. Confirmed diagnoses of 
EGA and LB in resident horses are a clear indicator that Canadian horses are at risk for 
exposure to tick-borne diseases  and characterization of risk factors in horses is warranted as 
the geographic range of the vector tick is predicted to expand further north and west in 
Canada (39,40,64,77,82,91).  
 In 2011 a small seroprevalence study of horses residing in SK, MB and ON was 
conducted (see chapter 2). Horses were tested for the presence of antibodies to A. 
phagocytophilum and B. burgdorferi by use of a point-of-care ELISA that is licensed for dogs 
but is claimed to be non-species-specific (28). Selected samples were also re-tested at a 
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commercial veterinary diagnostic laboratory using an IFA for EGA and an ELISA/Western 
Blot combination for LB. Seropositive horses were found in provinces with (ON and MB) and 
without (SK) known established populations of the Ixodes vector. The overall seroprevalence 
of EGA was 0.53% (95% CI: 0.09-2.12%) and the overall seroprevalence of LB was 1.6% 
(95% CI: 0.65-3.6%).  
  In a second study, additional serum samples submitted to Prairie Diagnostic Services Inc. 
(PDS) in Saskatoon, SK during April 2013 were tested with a point-of-care  ELISA as well as 
different serologic tests offered by  commercial veterinary diagnostic laboratories.  For EGA, 
samples were tested with two IFAs and for LB, samples were tested with an IFA, an 
ELISA/WB combination and a Lyme multiplex assay. Seropositive samples were identified 
for both organisms.   
 The aim of the study reported here was to identify potential risk factors for exposure of 
horses to EGA and LB in Canada. The hypothesis was that management factors do not differ 
between seropositive and seronegative horses. Mail-out surveys were used to obtain 
information about signalment, management factors including pasture access, travel history, 
and clinical history which were then compared between horses that tested seropositive or 
seronegative for EGA and LB, respectively, in the previous studies.     
4.3 Materials and Methods 
4.3.1 Serum samples  
 Samples for the previous 2 studies (n=426) were supplied from laboratory submissions to 
three provincial veterinary diagnostic laboratories, namely PDS, Saskatoon, Saskatchewan; 
the Manitoba Agriculture Food and Rural Initiatives Veterinary Diagnostic Services, 
Winnipeg, Manitoba; and the Animal Health Laboratory (AHL), Guelph, Ontario. A total of 
392 submissions were used for the current study; 34 submissions were excluded because one 
diagnostic laboratory declined participation in the study. To comply with the terms of the 
original agreements for supplying serum samples to the investigators, specifically to maintain 
anonymity of the horses and horse owners, all matching of sample identification numbers to 
individual horses, horse owners and submitting veterinary practices was done by the 
veterinary diagnostic laboratories rather than the investigators. Details are described under 
“survey distribution”.  
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 For the previous studies, samples were collected in 2011 (n=342) and 2013 (n=50). In 
2011, all samples were tested using the SNAP® 4Dx® ELISA (IDEXX Laboratories, Inc., 
Westbrook, ME); seropositive samples and a random selection of seronegative samples were 
re-tested for antibodies against A. phagocytophilum by laboratory-based IFA and for 
antibodies against B. burgdorferi by laboratory-based  ELISA confirmed with WB. In 2013, 
all samples were tested using the SNAP® 4Dx® Plus ELISA (IDEXX Laboratories), 2 
laboratory-based IFAs for antibodies against A. phagocytophilum and with laboratory-based 
IFA, ELISA confirmed with WB and Lyme multiplex assay for antibodies against B. 
burgdorferi. Samples that tested positive for antibodies against A. phagocytophilum or B. 
burgdorferi respectively, in any of the serologic tests were considered seropositive for the 
purpose of this study.  
4.3.2 Survey distribution 
 Information about signalment, management and clinical history was obtained through 
surveys that were mailed out to the horses’ owners.  Survey mail-outs were conducted in such 
a way as to blind the investigators and maintain the anonymity of the horses and horse 
owners.  Briefly, each survey was labeled with one sample identification (ID) number by one 
of the authors (GS). The diagnostic laboratories matched the sample ID to the horse’s name or 
other identifying information, the owner’s name and to the veterinary practice (or veterinary 
practitioner) who originally submitted the sample. The diagnostic laboratories mailed the 
surveys to the submitting veterinary practices (or veterinary practitioners), who were asked to 
pass on the surveys to the horses’ owners. Pre-paid envelopes for all mailings were supplied 
by the investigators.   
 Each mailed package contained the surveys as well as cover letters from both the 
investigators and the diagnostic laboratory explaining the study. Pre-paid business reply 
envelopes for return of the surveys to one of the investigators (GS) were also supplied. 
Owners were asked to return surveys within 6 weeks of the mail-out date and were allowed an 
additional 2 weeks to withdraw from the survey analysis. Horse owners responding to the 
survey were not required to identify themselves or their horse. Their name and contact 
information as well as the name or identifying information of the horse remained unknown to 
the investigators unless owners chose to disclose it. Horse owners were also given the option 
of contacting the investigators if they wanted to know the test results of their own horses. The 
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study was approved on ethical grounds by the University of Sas atchewan’s Behavioural 
Research Ethics Board (BEH #13-147). 
4.3.3 Survey design 
 Samples for the previous studies were submitted to the diagnostic laboratories in October, 
November and December 2011 or in April 2013 and the study reported here was performed 
from June to September 2013. To include information about at least one tick season prior to 
sample analysis, owners of horses whose serum samples were used in the 2011 study were 
asked to address the 2011 calendar year, and owners of horses whose serum samples were 
used in the 2013 study were asked to address the 14 months preceding sampling (January 
2012 – March 2013). Survey forms were worded accordingly (Figure 4.1 and 4.2).  
 The questions in the survey pertained to the signalment (age and sex) of the horses, 
duration of ownership, timing of pasture access, history of travel, history of diagnosis of EGA 
or LB by a veterinarian, known history of tick infestation and vaccination status with regard 
to LB.  
4.3.4 Data management and reporting 
 Horses were classified as seropositive or seronegative for EGA, and as seropositive or 
seronegative for LB, and survey responses are reported separately for each disease. As the 
potential risk factors for exposure was of interest, information (e.g. travel history) provided 
about time frames after sample collection was excluded. Information regarding travel history 
provided for the month of sample collection was also excluded as the majority of samples 
were originally submitted for equine infectious anemia testing. Results for these tests are 
typically required for travel or competition, and any travel in the same month was therefore 
expected to have taken place after sample collection.  
 For horses whose serum samples were used in the 2011 study, information concerning 
age and duration of ownership was adjusted to arrive at the horses’ age and duration of 
ownership at the time of sample collection. For example, if a horse’s age was reported as “10 
years” on the survey form, the horse was considered to be 8 years of age at the time of sample 
collection. If age was clearly identified as the age in 2011 on the form, the reported age was 
recorded. Age and duration of ownership were reported as median and range. The reason for 
inquiring about duration of ownership was to confirm the age of the horses at the time of 
sample collection. 
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Pasture access in the fall was of specific interest due to the presumably higher likelihood 
of horses to be infested with the adult stage of Ixodes which is active from September to 
December (13). Pasture access was therefore categorized as “pastured in the fall” or “not 
pastured in the fall”. Horses that were reported to be pastured “all year round” or those whose 
season of pasture access included “fall” were categorized as “pastured in the fall”. Horses that 
were reported to be pastured only in the “spring” or “summer” or that were not pastured were 
categorized as “not pastured in the fall”. Travel history was categorized as “travelled” or “did 
not travel”. “Travelled” referred to travel “outside the province but within Canada”, “to the 
US”, or “elsewhere”.  Travel history for horses that did not travel outside their province of 
residence was categorized as “did not travel”. Time of travel was reported as the month in 
which travel occurred or, in cases where owners reported travel but did not identify a month, 
as “un nown time”. Diagnosis of EGA or LB by a veterinarian,  nown tick infestation and 
vaccination against LB was categorized as “yes” or “no” according to responses.  Answers 
provided as “do not recall” or “do not  now” for any questions were considered as “no” 
answers.  
 Due to a low response rate, i.e. a low number of surveys returned, the data were not 
analyzed using statistical tests. 
4.4 Results  
 Response rate was 11.5% with 45 out of 392 surveys returned to us. One returned survey 
was excluded because the owner did not provide information about a specific horse but rather 
described the general management of the herd. This left 44 survey responses for descriptive 
reporting. Thirty-four responses concerned horses that were seronegative for both EGA and 
LB. Two survey responses concerned horses that were seropositive for EGA but seronegative 
for LB, and five survey responses concerned horses that were seropositive for LB but 
seronegative for EGA. Three survey responses concerned horses that were seropositive for 
both EGA and LB (Table 4.1 and 4.2). Ticks were only reported from horses tested in 2011. 
None of the horses was diagnosed with EGA or LB by a veterinarian or was vaccinated 
against LB.  
4.4.1 Horses seropositive or seronegative for EGA 
 The median age of the five horses that were seropositive for EGA (12 years) was higher 
than the median age of the 39 seronegative horses (3 years) although the age ranges were 
81 
 
similar (Table 4.1).  Four geldings and one mare were seropositive for EGA. Mares appeared 
over-represented in the seropositive group; 20% of horses in the seropositive group were 
mares while 10% of seronegative horses and 11% of horses overall were mares (Table 4.1).  
All of the horses seropositive for EGA had access to pasture in the fall while only 77% of the 
seronegative horses did. When looking at all horses, about 80% had access to pasture in the 
fall. Interestingly, ticks were reportedly not seen on the horses that were seropositive for 
EGA. In contrast, owners reportedly observed ticks on 15 of 39 seronegative horses (38%). 
Ticks were reportedly seen only in the spring and summer months (April to July 2011) (Table 
4.1).  
 All of the horses that were seropositive for EGA and 77% of the horses seronegative for 
EGA resided in SK. Overall, horses from SK were over-represented in the responses that were 
received (80%) considering the proportion of horses from SK that were tested  in both studies 
(60%). One of the five horses that were seropositive for EGA traveled to the US; however, the 
month of travel was not reported (Table 4.1). The proportion of seropositive horses that 
travelled (20%) appeared lower than that of the seronegative horses (28%). 
4.4.2 Horses seropositive or seronegative for LB  
 For LB, the median age and age range of seropositive and seronegative horses was 
similar (Table 4.2). Of horses overall, 86% were geldings whereas 75% of the horses that 
tested seropositive for LB were geldings. This suggests that mares were overrepresented in 
the seropositive group. Mares represented only 11% of all the horses but 25% of the 
seropositive horses were mares (Table 4.2). Of horses seropositive for LB, 88% had access to 
pasture in the fall compared to 78% of the seronegative horses and 80% of all horses. Similar 
to horses seropositive for EGA, ticks were reportedly not seen on any of the horses 
seropositive for LB. In contrast, ticks were seen on 15 seronegative horses (42%). Seven of 
the horses seropositive for LB (88%) resided in SK while 81% of the seronegative horses did. 
As stated earlier, horses from SK were over represented in the responses. Only one 
seropositive horse had travelled. The horse had travelled to Pennsylvania and reportedly 
resided there in the 5 months before sample collection in April 2013 (Table 4.2). This means 
that the horse spent the fall, when adult stages of Ixodes are active, in the US. Eleven of the 
seronegative horses (31%) had a travel history. 
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4.5 Discussion 
 Reported response rates of paper-based surveys are typically over 32% (112) while the 
response rate in our study was low (11.5%). The response rate for owners of horses sampled 
in 2011 (10.5%) was lower than that of owners whose horses were sampled in 2013 (18%), 
which may indicate that a longer time from sample collection affected our ability to reach the 
owners or their recall. All surveys were sent out by the diagnostic laboratories; however, it is 
unknown how many surveys were passed on by veterinary practices (or veterinary 
practitioners) and how many were actually received by the horses’ owners. Another limitation 
of the study, namely the fact that the surveys were an “afterthought” and were not planned 
from the beginning of the serologic studies, probably reduced compliance.  
 As identifying differences between horses testing seropositive or seronegative for EGA 
and LB, respectively, was attempted, it was essential to obtain information from seropositive 
and seronegative horses. While the proportion of surveys about seropositive horses for EGA 
(11%) was similar to the proportion of samples that were seropositive for EGA (10%), 
surveys about horses seropositive for LB were over represented (18%) compared to the 
proportion of samples that were seropositive for LB (8.5%). Overall the low response rate 
precluded statistical evaluation, such that it was not possible to truly test the hypothesis. 
However, the following interesting trends were identified and may warrant further 
investigation in future studies. 
 The median age of horses seropositive for EGA was higher than that of seronegative 
horses although the age ranges overlapped. Although the severity of clinical signs of EGA is 
considered to be age dependent, with older horses showing more severe clinical signs 
(4,13,87), the association between age and rate of infection is unknown. As measurable 
antibody titers may last up to 2 years (25), life time exposure does not necessarily explain a 
higher rate of seropositivity in the older horses.  
 Only 2 (20%) seropositive horses (one to EGA and one to LB) travelled, both to the US, 
while 10 (30%) of the seronegative horses travelled. The fact that more seronegative horses 
travelled does not support travel as risk factor for exposure. While the timing of travel for the 
LB-seropositive horse was consistent with the activity time of adult Ixodes, the time of travel 
to the US for the EGA-seropositive horse was not reported. While it is possible that time of 
travel was relevant to exposure of the EGA seropositive horses it is also possible that the 
travel to the US occurred after sample collection which would obviously be irrelevant for 
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exposure. Yet, the majority of seropositive horses were not reported to travel out of their 
province of residence which suggests that they were exposed to the causative organisms 
within Canada. Thus, these horses may have been exposed to infected Ixodes originating from 
established tick populations such as those known to be present in MB, or they could have 
been exposed to adventitious ticks arriving in non-endemic areas such as SK. While only one 
horse that resided in MB was seropositive to LB, the rest of the seropositive horses were from 
SK and the majority of them did not travel. Thus, one may assume that they were most likely 
exposed to adventitious ticks in SK. While it appears from our data that the majority of 
seropositive horses were exposed to adventitious ticks, it is worth mentioning that horses from 
SK were over-represented in our responses.  
 For the purposes of this study, seropositive horses were defined as those testing positive 
for antibodies in any of the serologic tests. It is essential to mention that test results for the 
same samples differed between the different serologic tests and that the proportion of positive 
results obtained in laboratory-based tests was higher than would be expected for horses in 
Canada. The possibility of false positive results should therefore be considered, which may 
have limited interpretation of our data. Further studies using more stringent criteria are needed 
in order to more accurately evaluate the risk of exposure in horses in Canada.    
 The adult stage of Ixodes, which is the stage most likely to infest horses, is active the fall 
(13,61). The majority of seropositive horses had access to pasture in the fall, which may 
support a higher risk of exposure for pastured horses. However, it was noticed  that most of 
the seronegative horses had access to  pasture in the fall as well, and the association of pasture 
access in the fall and testing seropositive for tick-borne diseases requires further investigation.  
 It was interesting to note that none of the horses seropositive for EGA or LB were 
observed to be infested with ticks. On the other hand, 15 of the seronegative horses were 
reported to have had visible tick infestation. Ticks were seen in the spring or summer that 
preceded sample collection in 2011. No ticks were reportedly seen by the owners of the 
horses tested in 2013. Based on the season of observation, it is possible that the ticks that 
infested these horses were Dermacentor species rather than Ixodes species that transmit EGA 
and LB.  
 D. variabilis and D. andersoni, which are among the most common ticks in Canada 
(1,3,113), are not able to maintain or transmit A. phagocytophilum and B. burgdorferi (2,114–
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117). Spring and summer are the seasons in which the adult stages of D. variabilis and D. 
andersoni are active (3) and it is possible that these species were observed on the horses.  
D. albipictus is able to maintain and transmit infection with non-pathogenic strains of A. 
phagocytophilum (115) and non-pathogenic strains may cause seroconversion. While the 
adult D. albipictus ticks are active in the winter, the nymphs are active later in the spring (3). 
D. albipictus is not able to maintain or transmit infection with B. burgdorferi (115).  
 It is possible that Ixodes, which are the major vectors for both A. phagocytophilum and B. 
burgdorferi, were simply not noticed by horse owners. Ixodes are significantly smaller than 
Dermacentor species (adults are 3mm in length versus 6 mm, nymphs are 0.6mm in length 
versus 1-2mm). The Ixodes are also darker and less easily identified.  
 As none of the horses was reportedly diagnosed with EGA or LB by a veterinarian, it was 
assumed that none of the horses had clinical signs of these diseases. Infection with A. 
phagocytophilum and B. burgdorferi does not necessarily cause disease and asymptomatic 
seropositive horses have been previously reported (13,50). It is also possible that infection 
with non-pathogenic strains of A. phagocytophilum, while not causing symptomatic infection, 
resulted in seroconversion. Current serologic tests do not differentiate between strains of A. 
phagocytophilum and it is not possible to differentiate between horses exposed to pathogenic 
or non-pathogenic strains based on serology.  
 In summary, we observed that the median age of horses that were seropositive for EGA 
was higher than that of the seronegative horses. Horses seropositive for EGA and LB resided 
in provinces with (MB) and without (SK) known established populations of Ixodes. The 
majority of seropositive horses did not travel in the year that preceded sample collection and 
it is therefore likely that they were exposed to infected vector ticks within Canada. Infestation 
with infected adventitious ticks carried by humans or animals such as migrating birds may 
explain exposure in these horses. The majority of seropositive horses had access to pasture in 
the fall; however, horse owners did not report seeing ticks on the seropositive horses. The 
small number of returned surveys did not allow for statistical analysis; however our data 
identify initial trends that can be investigated further in additional studies.  
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4.6. Figures  
Figure 4.1. Survey for owners of horses whose serum samples were tested for antibodies 
against A. phagocytophilum and B. burgdorferi in 2011. 
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 Figure 4.2. Survey for owners of horses whose serum samples were tested for antibodies 
against A. phagocytophilum and B. burgdorferi in 2013. 
 
 
87 
 
4.7. Tables  
 EGA+ (n=5) EGA- (n=39) 
Age (years): Median (range) 
 Not reported (n=1) 
12  (2-18) 
0 
3 (0.3-21) 
1 
Sex 
 Gelding (n=38) 
 Mare (n=5) 
 Stallion (n=1) 
 
4 
1 
0 
 
34 
4 
1 
Duration of ownership (years) 
 Median (range) 
 Not reported (n=2) 
 
5  (1.5-10) 
0 
 
2 (0-12) 
2 
Pastured in Fall  
 Yes (n=35) 
 No (n=9) 
 
5 
0 
 
30 
9 
Diagnosed with EGA or LB 
 Yes (n=0) 
 No (n=44) 
 
0 
5 
 
0 
39 
Ticks seen  
 Yes (n=15) 
 No  (n=29) 
 
0 
5 
 
15  
24 
Province of Residency  
 SK (n=36) 
 MB (n=6) 
 ON (n=2) 
 
5 
0 
0 
 
31 
6 
2 
Travel history 
 Travelled (n=12)  
 Did not travel  (n=32) 
 
1 
4 
 
11 
28 
Vaccinated against LB  
 Yes (n=0)  
 No (n=44) 
 
0 
5 
 
0 
39 
 
Table 4.1. Comparison of signalment, management and clinical history between horses 
testing seropositive (+) or seronegative (-) for equine granulocytic anaplasmosis (EGA).   
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 LB+ (n=8) LB- (n=36) 
Age (years): Median (range) 
 Not reported (n=1) 
3  (2-18) 
0 
4 (0.3-21) 
1 
Sex 
 Gelding (n= 38) 
 Mare (n=5) 
 Stallion (n=1) 
 
6 
2 
0 
 
32  
3 
1 
Duration of ownership (years)  
 Median (range)  
 Not reported (n=2) 
 
2 (1.5-5) 
1 
 
3  (0-12) 
1 
Pastured in Fall  
 Yes (n=35) 
 No (n=9) 
 
7 
1 
 
28 
8 
Diagnosed with EGA or LB  
 Yes (n=0) 
 No (n=44) 
 
0 
8 
 
0 
36 
Ticks seen  
 Yes (n=15) 
 No (n=29) 
 
0 
8 
 
15 
21 
Residency 
 SK (n=36) 
 MB (n=6) 
 ON (n=2) 
 
7 
1 
0 
 
29 
5 
2 
Travel history 
 Travelled (n=12) 
 Did not travel  (n=32) 
 
1 
7 
 
11 
25 
Vaccinated against LB 
 Yes (0) 
 No (n=44) 
 
0 
8 
 
0 
36 
 
Table 4.2. Comparison of signalment, management and clinical history between horses 
testing seropositive (+) or seronegative (-) for Lyme borreliosis (LB).  
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Transition to chapter 5 
The previous chapter described management factors in horses that tested seropositive or 
seronegative for EGA and LB, respectively. The information was obtained by asking horse 
owners to return anonymous surveys. The study revealed that most of the horses testing 
seropositive to either organism did not travel in the year that preceded sample collection, and 
that most of the seropositive horses lived in areas without known established populations of 
the Ixodes vector.  Although the majority of the horses were pastured in the fall, which is the 
time of activity for Ixodes adults that typically infest horses, none of the owners of 
seropositive horses reported that they had seen ticks on their horses at any time of the year. 
Published reports or reviews describing the ticks infesting horses are scarce. Thus, 
findings that horses are indeed exposed to tick-borne diseases in Canada indicated that further 
investigation of what ticks infest horses in Canada is needed. A passive surveillance study 
was conducted for the collection and identification of ticks infesting horses in SK, 
collaborating with Dr. Neil Chilton from the Department of Biology, University of 
Saskatchewan. The author of the thesis was responsible for receiving tick submissions from 
horses in SK in 2012 and 2013 and for transferring these to Dr. Chilton’s parasitology lab for 
identification. Dr. Neil Chilton and Mr. James Armstrong identified and categorized ticks. 
The author recorded tick species, stage and number, and followed up with horse owners, 
providing identification of the ticks submitted from the horses. We plan to submit this study 
for publication in the Canadian Veterinary Journal which will hold copyright. 
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5. PASSIVE SURVEILLANCE FOR HORSE TICKS IN SASKATCHEWAN 
5.1  Abstract 
Although tick-borne disease has been reported in horses in Canada, systematic 
descriptions of ticks infesting horses in Canada or elsewhere are rare.  
The aim of the study presented here was to describe ticks collected by horse owners and 
veterinarians from horses residing in Saskatchewan (SK) over a two-year period (2012-2013). 
The hypothesis of this study was that tick species known to be established in SK as well as 
adventitious ticks can be found on horses in SK. Ticks were categorized according to species, 
sex, life stage and degree of engorgement. Information about probable geographic locality of 
tick acquisition, estimated duration of tick attachment and travel history of the horse was 
requested along with tick submissions. None of the horses reportedly travelled in the 2 weeks 
prior to tick collection, suggesting that the horses acquired the ticks within SK. The number 
of submissions and the total number of ticks by species and month was recorded. During the 
study, a total of 833 ticks were collected from over 86 horses. Ticks were received from 
February to August 2012 and from February to July 2013. All ticks were Dermacentor 
species (D. albipictus, D. andersoni and D. variabilis). Timing of submission and geographic 
distribution were consistent with the reported peak activity of Dermacentor species and with 
previous reports of Dermacentor species distribution in SK. No Ixodes were received and 
none of the ticks received for this study were expected to put horses at risk for tick-borne 
diseases. A longer-term surveillance, including active surveillance, of horse ticks in SK may 
be warranted to further characterize the ticks infesting horses in SK and to monitor predicted 
changes in tick habitats.  
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5.2  Introduction 
Tick-borne disease occurs after transmission of a pathogenic organism by a vector tick to 
the tic ’s host. Tic s are considered a vector for a pathogen if the tic  feeds on a vertebrate 
host, is able to acquire the pathogen during a blood meal, maintains the pathogen through one 
or more life stages, and transfers the pathogen to another host during the next blood meal 
(61).  
Tick-borne diseases of horses in North America that are of relevance to Canadian horses 
are equine granulocytic anaplasmosis (EGA), Lyme borreliosis (LB) and equine piroplamosis. 
Of these, equine granulocytic anaplasmosis  caused by Anaplasma phagocytophilum and LB 
caused by Borrelia burgdorferi are the only reported tick-borne diseases in horses in Canada 
to date (4–7).  Both pathogens are transmitted by the tick vector Ixodes scapularis, which is 
currently established in a few locations in south east Canada, including areas of Southern 
Ontario (ON) and Quebec (QC),  Nova Scotia (NS), New Brunswick (NB) and south east 
Manitoba (MB) (38,39,111). Ixodes pacificus may also transmit EGA and LB and is currently 
established in a few locations in southern British Columbia (BC) (38,39). Established 
populations of I. scapularis or I. pacificus ticks have not been reported in SK and it is 
therefore likely that a SK horse diagnosed with EGA in 2010 (6) was exposed to infected 
adventitious Ixodes. Adventitious ticks are those brought into a non-endemic area on 
migrating humans or animals, such as migrating birds (40,118).  
Equine piroplasmosis, also called equine babesiosis, is caused by the blood protozoa 
Theileria equi and Babesia caballi. The tropical horse tick Dermacentor nitens is the natural 
vector in the US, but presence of this tick has not been reported in Canada (9). T. equi can be 
experimentally transmitted by D.  variabilis and D. albipictus, both of which are established 
in Canada, and by Rhipicephalus microplus (9) which does not occur in Canada.  Equine 
piroplasmosis is a reportable disease in the US and Canada and has not been reported in 
Canada to date. 
Dermacentor ticks are a genus of the ixodid ticks (hard ticks). The genus contains 33 
species and occurs on all continents except Australia (61). In North America, D. variabilis 
and D. andersoni are the most important species that infest livestock; D. albipictus mostly 
infests moose (61). D. variabilis and D. andersoni are two of the most common tick species in 
Western Canada. D. variabilis, also known as the American dog tick, occurs throughout 
southeastern SK, southern MB and ON (1,119). Isolated populations are also found in NS 
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(1,3). D. variabilis is usually found in geographic areas where summers are warm and humid 
(1), whereas  D. andersoni, also called the Rocky Mountain wood tick, occurs throughout the 
southern parts of BC and AB, and throughout southwestern SK (1,3,119) where summers are 
hot and dry (1). Usually, D. variabilis and D. andersoni will not be found in the same habitat 
(1–3) but occasionally, both species may be found together in areas that differ from their 
natural habitat, e.g. southern central SK which is dry and cold (1).  D. variabilis and D. 
andersoni are vectors for Rocky Mountain spotted fever (RMSF), a tick-borne disease caused 
by Rickettsia rickettsii (119,120). RMSF mostly affects humans although dogs  may 
occasionally become ill as well (120). Horses have not been reported to contract RMSF.  D. 
albipictus, also called the winter tick or moose tick, is the only Dermacentor tick whose life 
stages all occur on the same host.  The tick is found all across Canada and its habitat extends 
further north than that of D. andersoni and D. variabilis (3). 
Geographic range expansion of ticks is a concern in Canada; potential contributors are  
local migration of the ticks while on a local host, distant migration on birds migrating 
northward in the spring, and climate changes that may enable the survival and establishment 
of ticks in new locations (40,64,77,81,83,110). While passive and active surveillance of ticks 
collected from humans, companion animals and in the environment has been ongoing at the 
Department of Biology, University of Saskatchewan, we here report the first tick surveillance 
study focusing on ticks collected from horses in SK. To the best of our knowledge, published 
data about ticks infesting horses in SK are lacking. It was hypothesized that tick species 
known to be established in SK as well as adventitious tick species can be found on horses in 
SK. The objective of this study was to describe the species, sex, and life stage, stage of 
engorgement and geographic location of acquisition of ticks submitted from horses in SK 
over a 2-year period   
5.3 Materials and Methods 
5.3.1 Study design 
Passive surveillance of horse ticks in Saskatchewan took place between January 2012 and 
September 2013. The study was advertised through the mailing list of the Saskatchewan 
Veterinary Medical Association, the website of the Saskatchewan Horse Federation and the 
website of the Western College of Veterinary Medicine (WCVM), University of 
Saskatchewan. Advertisements were also posted in the reception area of the WCVM Large 
Animal Clinic and at the WCVM booth during the annual Saskatchewan Horse Expo in 
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Saskatoon. Veterinarians and horse owners were asked to submit ticks that were found on 
horses residing in SK.  
5.3.2 Tick submissions 
Horse owners and veterinarians were asked to submit ticks by mail to two of the authors 
(GS, KL). The submitters were asked to fill out a submission form for each horse from which 
ticks were collected, and to submit ticks from each horse separately. The submission form 
included questions about geographic location of acquisition of the ticks, travel history of the 
horse within the 2 weeks that preceded collection, date of tick collection and estimated time 
of attachment of the tic s. The horse’s name or other identification, as well as contact 
information were requested for the purpose of follow-up with the owners. Submitters were 
asked to submit ticks in sealed containers containing moist tissue to maximize preservation of 
the ticks.  
5.3.3 Tick identification 
Ticks were identified and catalogued by two of the authors (NC, JA). Tick species was 
recorded. Life stage was recorded as larva, nymph or adult and sex was recorded as male or 
female. Level of engorgement of female ticks was recorded as engorged or non-engorged. 
Ticks that were not preserved enough to allow their identification (e.g. dried out) were 
excluded from the study. 
5.3.4 Data reporting 
A ‘submission’ was defined as all the tic s from one horse that were received on a 
specific date. If a package arrived with no identification of the horse, it was considered as one 
submission. Repeated submissions from the same horse on different dates were counted as 
individual submissions. For each submission, the total number of ticks as well as the number 
of ticks by species and stage was recorded. The number of submissions (by species) and the 
total number of ticks (by species) was recorded and graphed by month (MATLAB R2013a, 
Mathworks Inc., US). Geographic location of tick acquisition was reported by city, town or by 
Dominion land survey parameters, according to information given by the submitter. Direction 
and distance from Saskatoon was described when city, town or a combination of section, 
township, range and meridian were given. The geographic location of acquisition was mapped 
manually using a free access royal map of SK and an online free province legal land converter 
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website (http://www.prairielocator.com/). Relevant travel history concerned travel outside the 
area of residence within 2 weeks before collection of the tick.  
5.4 Results  
A total of 833 ticks in 86 submissions were received over the duration of the study. In 
2012, all tick submissions occurred between February and August (543 ticks in 60 
submissions); no ticks were received in January and from September to December 2012. In 
2013, all tick submissions occurred between February and July (290 ticks in 26 submissions); 
no ticks were received in January, August or September 2013 (Figure 5.3 and 5.4).  
All received ticks were identified as Dermacentor species and species were identified as 
D. albipictus, D. andersoni and D. variabilis. Only adult ticks and nymphs were received and 
no larvae were identified. In both years, adult and nymphal D. albipictus were received 
whereas only adult D. andersoni and D. variabilis were received. The geographic distribution 
of the ticks according to species was similar in 2012 and 2013 (Figure 5.5 and 5.6).  None of 
the horses had reportedly travelled outside the area of residence in the 2 weeks prior to 
collection of the ticks. In 2013, 3 horses were reported to have travelled to neighboring farms, 
but this was not considered as travel outside the area of residence. Only 4 owners reported the 
estimated time of attachment of the ticks. These 4 owners suggested that the ticks were 
attached for approximately 2 hours (D. variabilis) one day (D. andersoni), 3-5 days (D. 
variabilis) and possibly for 2 weeks (D. andersoni and D. variabilis). 
5.4.1  Ticks received in 2012  
The number of submissions (Figure 5.3) and total number of ticks (Figure 5.4) was 
highest for D. variabilis, followed by D. albipictus and D. andersoni. The number of ticks per 
submission ranged from one to 94. One submission (in May) contained both D. albipictus and 
D. variabilis. The other submissions contained only one species. Two submissions (both in 
June) contained ticks collected from more than one horse. For another three horses, ticks were 
received twice, on different dates (April, May and June). On eight occasions, packages 
containing multiple submissions were received. Three packages were submitted by the same 
horse owner, containing submissions from one or two horses (all in May). 
D. albipictus 
One hundred and four D. albipictus ticks were received in nine submissions; five 
submissions occurred in February, three in March and one in May (Figure 5.3). The majority 
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of D. albipictus ticks were received in March (Figure 5.4). Both adult (n=62) and nymphal 
(n=42) stages were identified. Of the adults, there were 36 males, 23 un-engorged females and 
3 engorged females. D. albipictus ticks were received mainly from the Marsden area (near the 
AB border) and a few from 100 km northwest and 300 km south of Saskatoon. One 
submission of D. albipictus ticks originated further south in the province, near Assiniboia 
(Figure 5.5). 
D. andersoni 
Sixty D. andersoni ticks were received in two submissions, one in April and one in June 
(Figure 5.3). The majority of D. andersoni ticks were received in April (Figure 5.4).Only 
adult ticks were received. There were 26 males, 33 un-engorged females and 1 engorged 
female. D. andersoni ticks were received only from the southwest corner of the province 
(Figure 5.5), near Swift Current and Maple Creek.   
D. variabilis  
Three hundred and seventy-nine D. variabilis ticks were received in 50 submissions 
between April and August (Figure 5.3). The majority of D. variabilis ticks were received in 
June (Figure 5.4). Only adult ticks were received; there were 191 males, 81 un-engorged 
females and 107 engorged females. Most of the D. variabilis ticks were received from 
Saskatoon and areas surrounding Saskatoon (in the radius of 200 km), while some were from 
the south and south east areas of SK (Figure 5.5), near Regina and Yorkton. 
5.4.2 Ticks received in 2013 
The number of submissions (Figure 5.3) and total number of ticks (Figure 5.4) was 
highest for D. variabilis, followed by D. albipictus and D. andersoni. The number of ticks per 
submission ranged from one to 78. In May, one submission contained both D. variabilis and 
D. andersoni. All other submission contained only one species. One horse owner who sent 
ticks in 2013 had also sent ticks in 2012; however, the horse(s) from which ticks were 
collected were not identified. Two owners submitted ticks from more than one horse on 
different dates in April and May, respectively. One submission (in June) contained ticks from 
unidentified horse(s).  
D. albipictus 
Eighty-nine D. albipictus ticks were received in 5 submissions; 1 submission each 
occurred in February and March, and 3 occurred in April (Figure 5.3). The majority of D. 
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albipictus ticks were received in March (Figure 5.4). Both adult (n=71) and nymphal (n=18) 
stages were identified. Of the adults, there were 22 males, 45 un-engorged females and 4 
engorged females. D. albipictus ticks were received from Saskatoon and up to 100 km 
northwest of Saskatoon, as well as from the Lloydminster area, near the border with AB 
(Figure 5.6).  
D. andersoni 
Seventy-nine D. andersoni ticks were received in 6 submissions, of which 5 occurred in 
May and one occurred in June (Figure 5.3). The majority of D. andersoni ticks were received 
in May (Figure 5.4). Only adult ticks were received and there were 30 males, 8 un-engorged 
females and 41 engorged females. D. andersoni ticks were received from the southwest and 
south areas of the province (Figure 5.6), near Maple Creek and Assiniboia. 
D. variabilis 
One hundred and twenty two D. variabilis ticks were received in 16 submissions from 
May to July (Figure 5.3). The total number of D. variabilis ticks (n=60) and the number of 
submissions (n=7) received in May was similar to those received in June (n = 61 and n=8, 
respectively) (Figures 5.3 and 5.4). 64 adult males, 20 un-engorged adult females and 38 
engorged adult female ticks were received. D. variabilis ticks were received from Saskatoon 
and from areas up to 250 km south, southeast and east of Saskatoon, as well from the south 
area of the province near Assiniboia (Figure 5.6). One submission in May (Colonsay, SK) 
originated from a donkey. 
5.5 Discussion 
The passive surveillance of horse ticks in SK reported here took place between January 
2012 and September 2013. The aim of the study was to describe ticks that can be found on 
horses in SK. All ticks received from horses were Dermacentor species.  
The total number of tick submissions was lower in 2013 compared to 2012. Due to the 
fact that a passive surveillance was used to collect ticks, it is challenging to point out 
accurately why there was a difference in the numbers of tick submissions between 2012 and 
2013. However, there are a few possible explanations for this difference. One possible 
explanation concerns differences in environmental conditions between the first and second 
year of surveillance, which may have favored development of different tick species and stages 
in 2012 or inhibited their development in 2013 (3,113,119).  When comparing records of air 
98 
 
temperature and relative humidity in SK between 2012 and 2013 (personal communication 
with Environment Canada, St. Denis station, 40 km east of Saskatoon), it was interesting to 
note that the average temperature in the winter and spring months varied between the years. 
January 2012 was less cold than January 2013, with average temperatures of -8.7 ⁰C and -15.0 
⁰C, respectively. The average temperature in February 2012 (-8.9 ⁰C) was similar to that in 
February 2013 (-11.0 ⁰C). The spring of 2012 was characterized by relatively higher monthly 
average air temperatures compared to those in 2013. In 2012, the average air temperatures in 
March and April were -1⁰C and +3.6 ⁰C, respectively, whereas in 2013, these were -11.3 ⁰C 
and -2.7 ⁰C. In 2013, relative humidity was higher in January (82.8% versus 71.5%), February 
(86% versus 79%), April (76.2% versus 71.5%) and May (58.8% versus 52%) compared to 
2012. Considering the preferred relative humidity conditions in Dermacentor species, the 
differences in the average relative humidity in SK between 2012 and 2013 may not explain 
the differences in the number of ticks received between the years.  
Another possible explanation lies in the nature of a passive surveillance study. The 
success of this study was depended on the interest and willingness to help of veterinarians and 
horse owners in SK. As owners and veterinarians who submitted ticks were informed with the 
identity of the ticks they submitted, and as these ticks were probably of little clinical 
significance with regards to tick-borne diseases to their horses, their interest and motivation to 
submit new identified ticks may have declined over time. Only one owner submitted ticks in 
both 2012 and 2013; however, it was unknown whether submissions in both years occurred 
from one or more horses. Another factor potentially influencing the number of submissions 
was advertisement effort. While efforts were done to re-advertise the study in 2013, it was not 
possible to renew posting on the SK Horse Federation website, which was one of the sources 
used during 2012.  
D. albipictus  
Receiving D. albipictus ticks from horses in SK was not surprising as the ticks are known 
to occur in this province, and will infest large mammals such as moose, deer, cows and horses 
(3,121). Although the number of submissions (n = 8) and the total number of ticks (n = 104) 
received was higher in 2012 compared to 2013 (n = 5 and n = 89, respectively), the general 
pattern of submissions in both years was consistent with the expected life cycle of the tick. D. 
albipictus is a one-host tick that typically completes its life cycle in one year (3). Larvae hatch 
in the early fall and immediately start questing for a host.  Once on a host, the larvae feed and 
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immediately upon feeding molt to nymphs. The nymphs remain on the host for the fall and 
winter months, feed constantly and molt to the reproducing adult stages starting in January. 
The adult ticks are usually active from January to May, laying eggs in mid-summer (3). 
 D. albipictus ticks were received only in the months of February, March, April and May, 
with the highest number of D. albipictus ticks received in March 2012 and March 2013. Both 
nymphal and adult D. albipictus ticks were received in February and March of each year. 
Although it has been reported that nymphs may be found on their host during their molting, 
from November through February (121),  it was somewhat surprising that nymphs were 
received as late as February and March. It is possible that relative low temperatures in our 
geographical region delay the tic s’ development compared to other regions. Submissions 
later in the spring (in May 2012 and April 2013) contained only adult stages, mainly engorged 
females. It is possible that because D. albipictus are one host ticks and remain on one host, 
which ensures a relatively constant environment, variation in winter and fall temperatures 
between the years of collection did not have a major effect on the tic s’ life cycle. 
Lower numbers of nymphal compared to adult D. albipictus were received in both years. 
It is possible that the difference between the number of nymphal and adult stages that were 
received resulted from a failure to identify immature stages, due to their significantly smaller 
size. The fact that D. albipictus are one host ticks which occur on one host is probably the 
reason why it was the only species of which we received nymphs. While nymphs of the other 
species may occur on horses, horses are mostly infested with adult ticks. No larvae were 
received in our study. This was not surprising as this life stage mostly does not occur on 
horses. However, in the case of D. albipictus, in which all stages occur on the host, it is most 
likely that larvae were not identified due to their smaller size (Figure 5.1).   
D. andersoni  
Receiving D. andersoni from horses in SK was not surprising as D. andersoni have been 
reported to occur in SK and adult stages may infest horses (1,3,61). An increase in the number 
of submissions of D. andersoni was noticed in 2013 (n=6) compared to 2012 (n=2). Only 
adult D. andersoni ticks were received for the study. Adult D. andersoni ticks are typically 
active between April and June, with peak reproductive activity in May (3). In 2012, adult 
ticks were received in April and again in June; however, according to the accompanying 
questionnaire, ticks in the second submission may have been collected in late May or early 
June. In 2013, adult ticks were received in May and June but not in April. As described 
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earlier, the higher average temperature in April 2012 (+3.6 ⁰C) was likely more conducive to 
the tic s’ activity than the average temperature in April 2013 (-2.7 ⁰C), which was probably 
not favorable. However, average temperatures in May 2012 and May 2013 were 10.2 ⁰C and 
12.9 ⁰C, respectively, and likely favored reproduction activity equally. 
D. variabilis  
Receiving D. variabilis from horses in SK was not surprising as this species has been 
reported to occur in SK and adult stages may infest horses (1,3,61). D. variabilis ticks were 
received from April to August 2012 and from May to July 2013. Relative to 2012, the overall 
submission and number of D. variabilis was lower in 2013. The pattern of submissions in 
2012 suggested that adult ticks were active in April, with tick activity peaking in May and 
gradually declining throughout June, July and August. This pattern is typical for the activity 
of adult D. variabilis (3). The average ambient temperature in March 2012 (-1.0 ⁰C) and April 
2012 (+3.6 ⁰C) indicated favorable conditions for cessation of dormancy and stimulation of 
adult tick activity (3). In comparison, the average temperatures in March 2013 (-11.0 ⁰C) and 
April 2013(-2.7 ⁰C) were likely too low to stimulate tick activity. In May 2013, the average 
ambient temperature was 12.9 ⁰C, which should have favored activity of the reproductive 
stages of D. variabilis. The fact that submissions of D. variabilis first occurred in May 2013 
(versus April in 2012) and lasted until July suggested that environmental conditions 
influenced the delayed pattern of submission. The less favorable environmental temperatures 
may partially explain the lower numbers of adult D. variabilis submissions in 2013.  
The geographical distribution of tick submissions was consistent between 2012 and 2013 
and was compatible with other reports of the distribution of Dermacentor ticks in SK, which 
are based on active surveillance or on submissions of ticks collected from humans and 
animals other than horses (1,3). D. variabilis was primarily distributed in the south and 
southeast of the province, D. andersoni in the southwest of the province and D. albipictus was 
mostly extending further north and west, near the border of AB, between Marsden and North 
Battleford, but was occasionally submitted from south of Saskatoon.  
None of the ticks received for this study were expected to put horses at risk for tick-borne 
diseases. D. andersoni and D. variabilis are unable to maintain or transmit A. 
phagocytophilum causing EGA and B. burgdorferi causing LB (114,115). Conversely, D. 
albipictus reportedly can be infected with a non-pathogenic strain of A. phagocytophilum 
(115).  D. variabilis and D. andersoni are the main vectors for the Rickettsial agent causing 
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RMSF (2,119,122); however, RMSF has never been reported in horses.  Theileria equi, the 
causative agent of equine piroplasmosis has been experimentally transmitted by D. variabilis 
and D. albipictus (9);  however, the significance of this form of transmission in the context of 
naturally occurring disease is not clear. Equine piroplasmosis has not been reported in horses 
in Canada to date. 
In this study, information about any clinical manifestations of tick infestation, nor the 
horses’ physical condition were not requested. It would have been beneficial to collect that 
information in order to better understand possible clinical manifestations of tick infestation in 
horses. Two of the owners voluntarily reported that their horses suffered oozing lesions in the 
areas of tick attachment and that they seemed very itchy. Interestingly, only D. variabilis 
males were received from these horses, and while one male tick was attached (time of 
attachment unknown), none were engorged.  There are no descriptions in the literature that 
relate the severity of reaction to a tick bite to the sex or life stage of the tick. The fact that 
only male ticks were identified on these two horses does not rule out the possibility that the 
observed reaction was due to the bite of another tick. In fact, the observation that only one 
male tick was attached and none was engorged may suggest that these ticks were not 
responsible for the observed reactions.  It is thus possible that female ticks, which attach for 
longer periods of time and feed more, caused the reported reactions.  Hypersensitivity 
reactions in response to infestation with Dermacentor and Ixodes have been reported in horses 
(123) and the clinical significance of Dermacentor infestation in horses warrants further 
investigation.  D. albipictus infestation can cause severe anemia and debilitation in moose 
(121). Similar effects of Dermacentor tick infestation in horses are not reported but cannot 
exclude the possibility that severe infestation might carry health risks. 
No ticks were received in the fall and winter months and the end of summer 2013 
(January 2012, September-December 2012, January 2013 and August and September 2013). 
As adult stages of D. andersoni and D. variabilis, the two species that were most frequently 
received, have their peak activity in the spring and summer, the lack of submissions in the fall 
and winter months was expected for these species. It is also possible that many horses are not 
pastured in these colder months and therefore are less likely to be infested with ticks such as 
D. albipictus. As unfortunately owners were not asked about pasture housing in the 
submission forms, it is not possible to assess the likelihood of this possibility.  Another 
possible explanation is that fall and especially winter may be associated with decreased 
outdoor activity of horse owners and, consequently, decreased frequency of grooming and 
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inspection of their horses. This may explain why D. albipictus, whose adults start to be active 
as early as January (3) were not submitted until February of each year.  
No Ixodes were received in this study. In general, horses may be infested with adult 
stages of Ixodes in the fall months, or with immature stages (larvae and nymphs) in the spring 
and summer (3). Ixodes species (Figure 5.2) may be difficult to identify due to their smaller 
size relative to the Dermacentor species (Figure 5.1), which may in part explain the fact that 
no Ixodes were received for this study. Established populations of Ixodes have not been 
reported in SK to date; however, adventitious Ixodes have likely been responsible for the 
occurrence of EGA in at least 2 horses that did not travel outside of SK for years before 
diagnosis (2, and personal communication, Dr. Alain Fafard). Failure to identify Ixodes in this 
study therefore does not rule out the occurrence of these ticks in SK. The rate and prevalence 
of infection with A. phagocytophilum in adventitious Ixodes species has been described  
elsewhere (40,79,90,124,125). It was previously suggested that adventitious Ixodes species 
arriving in areas which are not endemic for Ixodes scapularis may gradually establish 
populations due to anticipated climate change favoring their survival and establishment 
(64,76,81,82,110). Once established, ticks may further become endemic for tick-borne 
diseases such as EGA and LB, which would increase the risk for horses in SK to acquire these 
tick-borne pathogens. The study reported here may serve as a good baseline for future studies 
that could evaluate changes in tick exposure of horses to monitor the predicted expansion of 
Ixodes habitats in Canada.  
 A limitation of the study presented here was the fact that complementary active 
surveillance by collecting ticks from horses in SK was not pursued. Passive surveillance is 
limited in that collection is not done systematically or done by trained investigators. Passive 
surveillance may have resulted in over-representation or under-representation of certain 
locations and horses from which ticks were collected. Observation of ticks on horses may be 
difficult at times, especially if immature stages are present. It is possible that many ticks went 
unnoticed. Management factors such as the use of the horses, grooming and inspection habits 
are likely to vary between owners and trainers. It is possible that information about the study 
was not equally distributed to horse owners, resulting in a biased submission pattern. This 
could have potentially caused a bias in the number of ticks submitted, location of submission 
and number of submissions. It is also possible that other species of ticks infest horses in SK 
but were not submitted for the study. Yet, this is the first report describing tick species 
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infesting horses in SK in a time period of 2 years, including the description of geographical 
distribution from where ticks were collected from horses.  
In summary, the findings of this study suggest that a variety of Dermacentor ticks infest 
horses in SK. The absence of relevant travel history of the horses suggests that all of them 
acquired the ticks within SK. As was expected, and partially supporting the study hypothesis, 
ticks that are known to be established in SK, i.e. D. albipictus, D. andersoni and D. variabilis 
were received from horses in SK. Ixodes species, which may occur as adventitious ticks in 
SK, were not received from horses in this study which does not support the second part of 
study  hypothesis. A longer-term surveillance, including active surveillance, of horse ticks in 
SK may be warranted to further characterize the ticks infesting horses in SK and to monitor 
predicted changes in tick habitats. 
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5.6 Figures  
 
Figure 5.1. The American dog tick, Dermacentor variabilis. Clockwise (from top left): 
nymph, larva, male, female. The figure is presented with permission from Laura Harrington 
(Department of Entomology, Cornell University, Ithaca, NY); pictures were taken by Kent 
Loeffler. Sizes of D. albipictus and D. andersoni are similar to those of D. variabilis. 
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Figures 5.2. The blacklegged tick, Ixodes scapularis. Clockwise (from bottom left): female, 
nymph, male. The figure is presented with permission from Laura Harrington (Department of 
Entomology, Cornell University, Ithaca, NY); pictures were taken by Kent Loeffler. 
Size and morphology of I. pacificus are similar to those of I. scapularis. 
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Figure 5.3. Tick submissions (number by species and month) received from horses in Saskatchewan between January 2012 and September 2013. 
All ticks were Dermacentor species. 
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Figure 5.4. Ticks (number by species and month) received from horses in Saskatchewan between January 2012 and September 2013. All ticks 
were Dermacentor species.
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Figure 5.5. Geographic distribution of tick submissions in SK (February-August 2012). Each 
symbol represents one submission. The average number of ticks per submission was 9 (range 
1-94). There were 60 submissions originating from over 60 horses; 2 submissions contained 
ticks collected from 3 or more horses.  
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Figure 5.6. Geographic distribution of tick submissions from horses in SK (February-July 
2013). Each symbol represents one submission. The average number of ticks per submission 
was 11 (range 1-78). There were 26 submissions originating from over 26 horses; 1 
submission contained ticks collected from 2 or more horses. 
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6. GENERAL DISCUSSION AND CONCLUSIONS 
The studies presented in this thesis evaluated different aspects of horse exposure to the 
tick-borne diseases equine granulocytic anaplasmosis (EGA) and Lyme borreliosis (LB) in 
Canada. As evidence for the expansion of the geographic range of their common vector is 
increasing (38,64,75,85), and EGA and LB have been reported in horses in Canada (4–8), a 
better understanding of the current risk of exposure for horses in at least parts of Canada was 
desirable.  
In the first study, it was hypothesized that seroprevalence of EGA and LB in SK, MB and 
ON is low.  A total of 376 equine serum samples from SK (n=202), MB (n=140) and ON 
(n=34) were tested using a point-of-care ELISA. For EGA, seropositive horses were found in 
SK and MB, and for LB, seropositive horses were found in SK, MB and ON. While a low 
seroprevalence for EGA and LB supported our first hypothesis, the small sample size did not 
allow statistical analysis to assess whether seroprevalence differed among provinces and 
additional studies are needed to answer this question. Yet, the finding of seropositive horses 
for EGA and LB in this study and previously reported cases of EGA in Canada support the 
need to consider EGA and LB in veterinary practice in Canada. 
As part of the first study, test results of the point-of-care ELISA were compared to the 
results obtained when re-testing the same samples by laboratory-based serologic tests. The 
hypothesis was that the assessment of a sample as seropositive or seronegative for EGA or 
LB, respectively, will not differ between the tests. A lack of agreement between the point-of-
care ELISA and an IFA for EGA, and only fair agreement between the point-of-care ELISA 
and an ELISA confirmed with WB for LB were found. Thus, our second hypothesis was 
rejected. The fact that seropositive horses were found in this study, together with the 
increasing concern over expansion of the geographic range of the vector, emphasizes the need 
for practical and reliable diagnostic tests for tick-borne diseases in horses. As varying levels 
of agreement were found between the point-of-care ELISA and laboratory-based serologic 
tests in the first study, further investigation of the agreement between available serologic tests 
was needed.   
In the second study the hypothesis was that the assessment of a sample as seropositive or 
seronegative for EGA or LB, respectively, is independent of the specific testing method used. 
A new set of equine serum samples (n=50) was tested by point-of-care ELISA and the 
samples were also tested for antibodies against A. phagocytophilum by IFA in two referral 
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laboratories, and for antibodies against B. burgdorferi by IFA, ELISA confirmed with WB 
and Equine Lyme multiplex assay in three referral laboratories. A lack of agreement was 
found between all serologic tests for EGA. Agreement between serologic tests for LB ranged 
from poor to fair. Thus our third hypothesis was rejected. It is suggested that differences in 
test results for the same samples were due to the different test methods and antigens used; for 
example, some assays use whole cell organisms while others use a variety of specific surface 
antigens. Generally speaking, laboratory-based serologic tests in referral laboratories yielded 
a higher number of positive results compared to the point-of-care ELISA. As this study was 
designed to detect seropositive, but not necessarily actively infected horses, it is possible that 
the point-of-care ELISA yielded false negative results for LB as it may not detect all 
antibodies that are produced during different stages of infection or post exposure. The point-
of-care ELISA is designed to only detect antibodies produced during active LB (against VlsE 
antigens) (28), and is therefore not optimal for detection of antibodies in cases of very acute 
infection or in exposed but not actively infected animals. However, it is also possible that 
false positive results were obtained in referral serologic tests for EGA and LB due to cross-
reactivity with antibodies against similar organisms. Interestingly, 14% of the samples that 
were tested for this study were seropositive for both EGA and LB, suggesting that co-
exposure in horses in Canada should be taken into consideration.  
As historical or clinical data for the tested horses were not available, it is not possible to 
draw any conclusions about the clinical usefulness of the evaluated serologic tests. Although 
the aim was not to compare test performance for detection of antibodies in clinical cases, it is 
important to note that test interpretation in the context of clinical diagnosis of EGA and LB 
requires consideration of the clinical signs and history of exposure. Future studies should aim 
to standardize serologic tests for EGA and LB in horses, and establish approaches for 
screening horses with regards to methodology and interpretation. This is particularly 
important in non-endemic areas (86) where the positive predictive value of serologic testing is 
low, such as is the case when assessing seropositivity in horses in Canada where tick-borne 
diseases are currently uncommon.  
As a fair number of seropositive samples were found in the first two studies, it was of 
interest to investigate whether seropositive horses were likely exposed within Canada and to 
identify potential risk factors for exposure of horses to EGA and LB in Canada. In the third 
study, it was hypothesized that management factors do not differ between horses that are 
seropositive or seronegative for EGA or LB, respectively. As samples for the first two studies 
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were obtained without identifying information, a mail-out survey was designed to contact 
horse owners. 392 surveys were sent out to the owners of the tested horses; to maintain 
confidentiality, surveys had to be mailed out via the laboratories that supplied the samples and 
the veterinary practices that originally submitted the samples. Surveys pertained to signalment 
of the horses, timing of pasture access, tick infestation history, province of residence and 
history of travel as well as previous diagnosis of EGA or LB by a veterinarian. Unfortunately, 
response rate was low at 11.5% and we could not conduct statistical analysis to assess 
differences in management factors between seropositive and seronegative horses. Thus, we 
could not truly test our fourth hypothesis. However, several interesting potential differences 
were noted and may serve to generate hypotheses for future studies. It was noticed that the 
majority of seropositive horses were pastured in the fall months and, according to their place 
of residence and lack of recent travel history, were likely to have encountered the diseases 
within Canada. The median age of the seropositive horses for EGA was higher (12 years) than 
the median age of the seronegative horses (3 years). While older horses were previously 
reported to present with more severe clinical signs, potential differences in the rate of 
infection with EGA in adult horses have not yet been reported. None of the seropositive 
horses were reported to be infested with ticks, which was surprising although it could be 
explained by a lack of recognition of horse ticks by the owners. The data indicated trends 
related to the exposure of horses to the causative organisms of EGA and LB within Canada, 
which will be important to further investigate in future studies.  
The fourth study addressed the fact that, in general, data about ticks infesting horses are 
rare in the literature and lacking in Canada. It was surprising that tick infestation was not 
reported for seropositive horses in the previous study and thus, the aim was to describe the 
ticks infesting horses. The focus was on horses from SK, where a case of EGA had been 
reported (6) although Ixodes species are not known to be endemic in this province. The 
relative ease of recruiting participants and the direct applicability to horse owners in SK were 
important considerations in the design of the fourth study.  It was hypothesized that tick 
species known to be established in SK, as well as adventitious ticks, can be found on horses in 
SK.  A passive surveillance study of horse ticks took place in 2012 and 2013. Ticks were 
received and identified with the collaboration of Dr. Neil Chilton’s parasitology laboratory at 
the Department of Biology (U of S). Species, sex, life stage and stage of engorgement were 
recorded. A total of 833 ticks, collected from over 86 horses, were received between February 
and August 2012 and between February and July 2013. All ticks were Dermacentor species, 
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which were previously reported to occur in SK (1,3). Timing of submission  of specific tick 
species and life stages was compatible with the tic s’ reported life cycle (1,3). A future study, 
preferably involving active surveillance of ticks on horses in SK, would likely help to further 
characterize and understand patterns of ticks infesting horses in SK.  Although none of the 
ticks received for this study were expected to put horses at risk for tick-borne diseases, the 
possible clinical relevance of the infestation with these Dermacentor species may warrant 
further investigation. As evidence for exposure of horses in SK to adventitious Ixodes exists, 
and given the published predictions for expansion of tick habitats, studies to monitor changes 
in tick habitats in SK may further be warranted. 
6.1. Future studies 
Seropositive horses for EGA and LB can be found in Canada. According to a point-of-
care test, seroprevalence of EGA and LB was low. Continuous assessment of seroprevalence 
in horses in Canada is warranted in order to monitor changes in level of exposure.  
Despite the low seroprevalence of tick-borne diseases in horses at the present time, there 
is a need to establish and standardize approaches to serologic testing and screening for EGA 
and LB, as the risk for exposure to the tick vectors in Canada is expected to increase 
(40,64,77,81,82,95).  Future studies should address the lack of gold standard serologic tests 
for EGA and LB in horses. Validation should include confirmation with bacteriological and 
molecular methods, or pathology, of known or experimentally infected animals.  
Standardization of test methods and interpretation should ideally be implemented.  
According to the survey study, horses seropositive for EGA and LB were most likely 
exposed to the causative organisms within Canada. Future studies should address possible risk 
factors, specifically pasture access in the fall, for increased exposure in horses in Canada. 
Horses in SK were found to be infested with 3 Dermacentor species that are known to be 
established in SK. Ixodes species were not received from horses in SK although evidence 
exists for the exposure of at least 2 horses in SK to adventitious Ixodes. Ongoing active and 
passive surveillance efforts are needed to monitor changes in tick infestation in horses in SK.   
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